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1  Introduction 
This CDISC Therapeutic Area Data Standards User Guide for Alzheimer’s Disease and Mild Cognitive Impairment 
(TAUG-Alzheimer’s) was developed under the Coalition for Accelerating Standards and Therapies (CFAST) 
initiative. 
 
CFAST, a joint initiative of CDISC and the Critical Path Institute (C-Path), was launched to accelerate clinical 
research and medical product development by facilitating the establishment and maintenance of data standards, 
tools, and methods for conducting research in therapeutic areas important to public health. CFAST partners include 
TransCelerate BioPharma Inc. (TCB), the United States Food and Drug Administration (FDA), and the National 
Cancer Institute Enterprise Vocabulary Services (NCI EVS), with participation and input from many other 
organizations.  
1.1 Purpose 
This document comprises Version 2.0 (v2.0) of the Alzheimer’s disease-specific Therapeutic Area User Guide 
(TAUG-Alzheimer’s) to be used as a supplement to the CDISC Study Data Tabulation Model (SDTM) 
Implementation Guide for Human Clinical Trials (SDTMIG). This user guide was prepared by the CFAST 
Alzheimer’s Development Team with participation from the Critical Path Institute’s Coalition Against Major 
Diseases (CAMD), and with input from the Alzheimer’s Disease Neuroimaging Initiative (ADNI). It is intended to 
guide the organization, structure, and format of standard Alzheimer’s disease (AD) and mild cognitive impairment 
(MCI) clinical trial tabulation datasets that can be used to support data review and analysis and submitted to a 
regulatory authority such as the FDA.  
 
With regard to clinical trials of AD and MCI, this guide describes a specific implementation of a subset of the 
domains whose general implementation is described in the current version of the SDTMIG. This document also 
makes use of newly drafted SDTM-based domains, and shows rules for and examples of implementing these 
domains specifically for trials of Alzheimer’s disease or mild cognitive impairment. 
 
This document does not replace, supersede, nor otherwise override any rules or requirements of the current 
SDTM and SDTMIG. Knowledge of this document alone is not a substitute for knowledge of SDTM nor is it 
sufficient to produce complete, SDTM-compliant regulatory submissions of Alzheimer’s or MCI clinical trials 
data. The TAUG-Alzheimer’s v2.0 should be used in close concert with the most current version of the SDTMIG 
and the most current version of the CDISC Study Data Tabulation Model (available at 
http://www.cdisc.org/standards). The SDTM describes the general model for representing clinical study data that is 
submitted to regulatory authorities and should be read prior to reading the SDTMIG. An understanding of both of 
these documents is required before attempting to read and understand the TAUG-Alzheimer’s v2.0. 
 
This document is intended for companies and individuals involved in the collection, preparation, and analysis of 
clinical data that will be submitted to regulatory authorities. 
 
Domains for which there are no current Alzheimer’s-specific rules are not included in this document. For 
information on these domains, refer to the current version of the SDTM/SDTMIG and other CDISC supplemental 
guides.  
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1.2 Organization of this Document 
This TAUG-Alzheimer’s v2.0 uses a transitional format, between 1) that of the legacy therapeutic area user guides 
that mirrored the SDTMIG in their organization, and 2) the style of therapeutic area user guides developed under the 
CFAST initiative and piloted by the TAUG-Asthma, which have a more clinically oriented organization. 
 
•  Section 1, Introduction, provides an overall introduction to the purpose and goals of the Alzheimer’s 
disease project.  
•  Section 2, Subject and Disease Characteristics, covers data that are usually collected once at the beginning 
of a study. 
•  Section 3, Disease Assessments, covers data that are used to evaluate disease severity, control, or 
progression. These are usually collected repeatedly during a study, and are often used as efficacy endpoints. 
•  Appendices provide additional background material and describe other supplemental material relevant to 
Alzheimer’s disease.  
 
A list of domains used in the examples in this document, and the sections in which they appear, are given below. 
The examples in this user guide, which include devices domains, record ancillary devices only. Unpublished draft 
domains are maintained on the CDISC Portal under Teams Projects/ SDTM/ Working Documents for Production 
Release. 
 
Domains from SDTMIG  Section(s) 
Interventions 
AG – Procedure Agents*  3.2.1.2, 3.2.2.2 
PR – Procedures  3.1.2, 3.2.1.2, 3.2.2.2 
Events 
MH – Medical History  2.2.1, 2.3.1 (APMH) 
Findings 
LB – Laboratory Test Results  3.1.2 
MO – Morphology  3.2.1.2 
NV –Nervous Systems Findings*  3.2.2.2 
* Domain was not published in SDTMIG 3.2 and is not final.  
 
Domains from SDTMIG-PGx*  Section(s) 
Biospecimen Domains 
BE – Biospecimen Event  3.1.2 
BS – Biospecimen  3.1.2 
Pharmacogenomics/Genetics Domains 
PF – Pharmacogenomics Findings  2.1.1 
*Implementation guide is not final.  
 
Domains from SDTMIG-MD  Section(s) 
DI – Device Identifier  3.1.2, 3.2.1.2, 3.2.2.2 
DU – Device In-Use  3.1.2, 3.2.1.2, 3.2.2.2 
DO – Device Properties  3.1.2, 3.2.1.2, 3.2.2.2 
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1.3 Concept Maps 
This document uses concept maps to explain clinical processes and research concepts. Concept maps, also 
sometimes called mind maps, are diagrams which include “bubbles” representing concepts/ideas/things and labeled 
arrows that represent the relationships between the concepts/ideas/things. They are generally easier to draw and 
more accessible than more formal modeling diagrams, such as Unified Modeling Language (UML) diagrams. 
 
 
Color Coding Key for Concept Maps 
 
The diagrams in this document use the color-coding shown above. The classification of concepts represented by 
these colors is based on classes in the BRIDG model. These colors have been used to highlight concepts that occur 
commonly in clinical data, and therefore give rise to common patterns of data. 
1.4 Controlled Terminology 
Terminology applicable to CDASH data collection fields is either in production or under development by the 
CDISC Terminology Team at the time of publication of this document. Production terminology is published by the 
National Cancer Institute’s Enterprise Vocabulary Services (NCI EVS) and is available at: 
http://www.cancer.gov/cancertopics/cancerlibrary/terminologyresources/cdisc.  
 
CDISC Controlled Terminology is updated quarterly. Because this document is a static publication, it refers readers 
to the NCI EVS page for CDISC terminology (at the link given above). For the same reason, this document cannot 
claim to use controlled terminology in either the lists of laboratory tests or in the examples provided; users should 
not refer to these as the ultimate authority on what terms to use.  
1.5 Relationships to Other Standards 
This section describes the relationship of this document to other standards, whether CDISC or external. This 
document does not replace the foundational CDISC standards or their implementation guides. The user should read 
those standards and implementation guides before applying the advice in this user guide. 
 
This TAUG-Alzheimer’s v2.0 is intended to replace the Alzheimer’s disease SDTM User Guide v1.0. The examples 
contained in this document were developed to expand upon work published in the SDTMUG-Alzheimer’s v1.0 in 
order to make the guide more useful in clinical studies, with a particular emphasis on early-disease assessments.  
 
The primary sources of inputs for new implementations of the standard shown in this version were the Alzheimer’s 
disease Neuroimaging Initiative (ADNI, http://www.adni-info.org/) and the biomarkers working group of the 
Coalition Against Major Diseases (CAMD), a program of the Critical Path Institute (www.c-path.org). Of the data 
specified by these two sources, the scope was limited to three major areas: clinical scales of cognition/function, 
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imaging biomarkers, and cerebrospinal fluid (CSF) biomarkers. Note that all clinical scales implemented for 
Alzheimer’s disease are maintained as standalone supplements maintained on the CDISC website. See Section 3.3 
for details. 
 
This document uses domains and assumptions that are not final at the time of publication, and are therefore subject 
to change or deletion without formal notice. Please check the most recent versions of the SDTM and SDTMIG to 
ascertain their current status.  
•  The Nervous System Findings (NV) domain is still a work in progress (i.e., a “draft” domain) that has not 
appeared prior to this document. 
•  The Procedure Agents (AG) domain is a draft domain which first appeared as a part of the TAUG-Asthma 
v1.0 package.  
•  The Biospecimen (BS) and Biospecimen Event (BE) domains are draft domains expected to be released as 
part of the SDTM Implementation Guide for Pharmacogenomics/Genetics v1.0. 
•  The Procedures (PR) domain has been through public review and will be released with SDTM v1.4 and 
SDTMIG v3.2. 
•  The Morphology (MO) domain has been through public review and will be released with SDTM v1.4 and 
SDTMIG v3.2. 
•  The Pharmacogenomics Findings (PF) domain has appeared previously as a part of the Virology 
Therapeutic Area Data Standards User Guide v1.0, but is still a work in progress. The most recent version 
of this domain to date is included in this package.  
 
In some cases when a definitive SDTM modeling approach does not exist, a suggested approach is offered but may 
be subject to change over time.  
 
There are multiple types of data that have existing CDASH and SDTM standards that can be used in Alzheimer’s 
disease studies without additional development or customization, such as Demographics, Adverse Events, Clinical 
Events, Concomitant Medications, etc. Domains whose uses are not explicitly represented in the examples within 
this document can still be used according to the rules of those domains as needed. Refer to the current SDTMIG for 
implementation examples using those domains. 
1.5.1 Summary of Changes from Previous Version 
•  Added examples detailing the data modeling of assays and protocol parameters used in the generation of 
the CSF biomarkers endpoints shown in Version 1.0 Laboratory Results (LB). Those examples are still 
shown in Version 2.0, but now have detailed sample collection and handling parameters represented in 
various other domains as well. 
•  Added examples of imaging biomarkers including the actual endpoints (volumetric, Standard Uptake Value 
Ratios) and the imaging protocol parameters used to generate these endpoints (via MRI, PET, and 
PET/CT). 
•  Added ten additional clinical scales relevant to AD and MCI to the Questionnaire Supplements to the 
SDTMIG maintained as separate documents on the CDISC website. 
•  Demographics domain (DM) examples were removed. There are no AD-specific demographics rules that 
should be standardized across studies. Sponsors should refer to the DM domain in the SDTMIG for details 
on creating this dataset. 
•  Family history was moved from Medical History (MH) to the Associated Persons Medical History 
(APMH) Domain. 
•  ApoE genetics data examples were moved from the Subject Characteristics (SC) domain to the 
Pharmacogenomics Findings domain (PF). 
•  The terminology for handling “Date of Onset of Cognitive Problem” in the Supplemental Qualifiers 
domain (SUPPMH) was changed to match other published guides. 
 
 
 
 
 
Page 7 
December 16, 2013 
© 2013 Clinical Data Interchange Standards Consortium, Inc. All rights reserved 
Provisional CDISC Therapeutic Area Data Standards: User Guide for Alzheimer’s Disease (Version 2.0) 
1.6 Known Issues 
•  Additional assumptions for Alzheimer’s-specific implementation of the domain examples demonstrated in 
this guide are contained in Appendix C and these assumptions should be applied when representing domain 
data for Alzheimer's studies. Since Therapeutic Area User Guides are not arranged by domain like the 
SDTMIG, examples of domains may appear in multiple sections together with the concepts covered in 
those sections, thus precluding a single, logical placement for assumptions for general domains that 
reappear in the TAUG.  CDISC recognizes that including these in an appendix this is not ideal. This may be 
addressed in future releases. 
•  Software analysis is represented as an analytical method in the imaging examples contained in the PET and 
MRI sections, and the name and version of the software is represented in Supplemental Qualifiers. Some 
regard this software as a standalone device. Therefore, it may be represented in the device domains in 
future releases pending CDISC SDS review and decision. 
•  CDISC SRC has recommended that only CDASH-compliant CRF examples be shown in CDISC guides. 
The example CRF in the Associated Persons Medical History example is not CDASH-compliant. This will 
be addressed in a future release.” 
•  Users should refer to SDTMIG section 4.1.2.4 for rules and recommendations on use of case for text 
submitted in data. Some values shown in the example values do not strictly adhere to these 
recommendations, particularly for --TRT, --TERM, --ORRES, DIVAL, and QVAL variables.
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2  Subject and Disease Characteristics 
2.1 Genetics of Alzheimer’s Disease 
Specific variants of the apolipoprotein E (ApoE) gene have been implicated in the development and progression of Alzheimer’s. As with any gene, an individual 
with a normal number of chromosomes (46) would have two copies (alleles) of the ApoE gene. There are three possible alleles of the ApoE gene, numbered as 
“2,” “3” and “4.” As such, investigators are primarily interested in a categorical genotype notation that indicates which of three possible isoforms a subject 
carries on each of his or her two alleles. Determination of genotype may be done by a variety of genetic testing methods, such as restriction fragment length 
polymorphism (RFLP) analysis. The results come in the form of a numerical representation of each of the two alleles a subject carries, giving the following 
possible six categorical combinations: “2-2”, “2-3”, “2-4”, “3-3”, “3-4” or “4-4”. Subjects who carry two copies of isoform 4 (“4-4”) are widely regarded to have 
a predisposition to developing Alzheimer’s and showing faster disease progression. Isoform 3 is considered neutral whereas isoform 2 may be protective against 
Alzheimer’s, but this has not yet been confirmed. Ongoing research seeks to understand the role and impact that the various combinations of these isoforms have 
on disease course. Subjects who are heterozygous for any given isoform (e.g., subjects who carry only one copy of isoform 4) may have a different disease 
course than subjects who are homozygous for any isoform (e.g., subjects who carry isoform 4 on both alleles), therefore it is important to record the results of 
each allele as a separate record as opposed to concatenating both allele results in one record, to allow for easier sorting of each allele independently 
 
This section explains how to represent the various combinations of isoforms that may be coded on each allele as determined by genetic testing. 
2.1.1 Examples for the Genetics of Alzheimer’s Disease 
Example 
This example shows the genotyping result for the Apolipoprotein E (ApoE) gene as two allele results for two subjects. Genotyping information is represented in 
the Pharmacogenomics Findings (PF) domain.  
 
Rows 1-2:   Show how to represent the results of a restriction fragment length polymorphism (RFLP) analysis (shown in PFMETHOD) used to make the 
determination of the isoforms represented by each allele of the Apolipoprotein E gene present in the subject. PFGENRI shows that the region of 
interest for this analysis was the Apolipoprotein E gene.  
Rows 3-4:   Show the results of the same analysis for another subject. 
 
pf.xpt 
Row STUDYID DOMAIN USUBJID PFSEQ PFTESTCD PFTEST PFGENTYP PFGENRI  PFCAT  PFORRES  PFSTRESC  PFMETHOD  PFBLFL VISITNUM  PFDTC 
1  ABC123  PF  AD01-101  1  ALE  Allele  GENE  ApoE  GENE 
EXPRESSION  3  3  RFLP 
ANALYSIS  Y  1  2013-05-22 
2  ABC123  PF  AD01-101  2  ALE  Allele  GENE  ApoE  GENE 
EXPRESSION  4  4  RFLP 
ANALYSIS  Y  1  2013-05-22 
3  ABC123  PF  AD01-102  1  ALE  Allele  GENE  ApoE  GENE 
EXPRESSION  4  4  RFLP 
ANALYSIS  Y  1  2013-05-22 
4  ABC123  PF  AD01-102  2  ALE  Allele  GENE  ApoE  GENE 
EXPRESSION  4  4  RFLP 
ANALYSIS  Y  1  2013-05-22 
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2.2 Medical History 
The following section describes how to represent medical history, both for Alzheimer’s/MCI as well as general medical history terms. Note that neither 
MHTERM nor MHCAT are subject to controlled terminology. These examples are intended to highlight how the primary diagnosis may be categorized 
differently from general medical history, and how using generalized MHTERM values for Alzheimer’s disease and Mild Cognitive Impairment is useful when 
multiple MHDECOD values may result from coding these terms to standard dictionaries. Sponsors should decide if they intend to use such dictionaries, and then 
decide which terms apply to their subjects’ diagnostic criteria.  
 
Since formal diagnosis of Alzheimer’s is challenging, many investigators are also interested in collecting date of onset of symptoms. Reporting this onset date is 
also shown below. 
2.2.1 Examples for Medical History 
For additional assumptions, see Appendix C. 
 
Example 1 
Below are specific Alzheimer’s/MCI Medical History examples for representing: 
•  General medical history entered as free text 
•  Primary diagnosis information 
 
Rows 1, 4, 7: MHCAT shows the PRIMARY DIAGNOSIS for three separate subjects, one with Alzheimer’s disease and two with mild cognitive impairment. 
Note that in this case MHDECOD is not populated.  
Rows 2-3, 5-6:  Indicate general medical history with MHCAT=GENERAL 
 
mh.xpt 
Row  STUDYID  DOMAIN  USUBJID  MHSEQ  MHTERM  MHDECOD  MHCAT  MHSTDTC 
1  ABC123  MH  AD01-101  1  Mild Cognitive Impairment    PRIMARY DIAGNOSIS  2001-05 
2  ABC123  MH  AD01-101  2  Blind Left Eye  Blindness unilateral  GENERAL  1999-07-07 
3  ABC123  MH  AD01-101  3  Traumatic Brain Injury  Traumatic brain injury  GENERAL  2005-03-28 
4  ABC123  MH  AD01-102  1  Alzheimer's Disease    PRIMARY DIAGNOSIS  2003-05 
5  ABC123  MH  AD01-102  2  Partial Gastrectomy  Gastrectomy  GENERAL  2006-06-21 
6  ABC123  MH  AD01-102  3  Arterial Hypertension  Hypertension  GENERAL  2006-07-26 
7  ABC123  MH  AD01-103  1  Mild Cognitive Impairment    PRIMARY DIAGNOSIS  2002-07 
 
Example 2: Onset of Symptoms 
There is some controversy over the method of recording the onset of symptoms. This example uses Supplemental Qualifiers, but this approach is under 
evaluation by the SDS team and may be revised in the future.  
 
The onset of symptoms date (QNAM=MHOSDTC) is when the symptoms of Alzheimer’s disease or mild cognitive impairment were first observed by the 
subject or a family member. The actual diagnosis date (MHSTDTC) is the date the subject’s physician officially diagnosed the disease. Where collected, onset 
date of symptoms (for either Alzheimer’s or MCI) should be mapped to SUPPMH as in the following example. According to precedent, QNAM is MHOSDTC 
and QLABEL is “Onset of Symptoms Date”. 
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suppmh.xpt 
Row  STUDYID  RDOMAIN  USUBJID  IDVAR  IDVARVAL  QNAM  QLABEL  QVAL  QORIG  QEVAL 
1  ABC123  MH  AD01-101  MHSEQ  1  MHOSDTC  Onset of Symptoms Date  1999-05  CRF  MOTHER 
2  ABC123  MH  AD01-102  MHSEQ  1  MHOSDTC  Onset of Symptoms Date  2000-02  CRF  FATHER 
3  ABC123  MH  AD01-103  MHSEQ  1  MHOSDTC  Onset of Symptoms Date  1998  CRF  STUDY SUBJECT 
 
2.3 Family History 
Understanding familiar patterns of dementias may be useful to investigators. This section describes how to represent family history using the Associated Persons 
Medical History (APMH) domain.  
2.3.1 Examples for Family History 
Example 
In this example, subjects were asked about their family history with Alzheimer’s disease and MCI in the following manner:  
 
Family History 
List any first or second degree family members (parents, children, siblings, grandparents, uncles, and aunts) 
diagnosed with Alzheimer’s disease or mild cognitive disorder. 
Relationship to Subject  Biological 
Relative? (Y/N) 
Diagnosed  Date of 
Diagnosis  Alzheimer’s  MCI 
        _ _ /_ _ /_ _ _ _ 
        _ _ /_ _ /_ _ _ _ 
        _ _ /_ _ /_ _ _ _ 
        _ _ /_ _ /_ _ _ _ 
 
MHTERM has been populated with Alzheimer's disease or Mild Cognitive Impairment and MHCAT with PRIMARY DIAGNOSIS. The values in SREL have 
been populated with terms from the “Relationship to Subject” codelist in the SDTM controlled terminology document.  
 
Rows 1 - 4:  Display the Medical History information for relatives of subject AD01-101. 
Rows 5 - 7:  Display the Medical History information for relatives of subject AD01-102. 
 
apmh.xpt 
Row  STUDYID  DOMAIN  APID  MHSEQ  RSUBJID  SREL  MHCAT  MHTERM  MHDTC  MHSTDTC 
1  ABC123  APMH  AP_01  1  AD01-101  MOTHER, BIOLOGICAL  PRIMARY DIAGNOSIS  Alzheimer's Disease  2011-03-15  1975-05 
2  ABC123  APMH  AP_02  1  AD01-101  SISTER, BIOLOGICAL  PRIMARY DIAGNOSIS  Mild Cognitive Impairment  2011-03-15  2000-07-15 
3  ABC123  APMH  AP_03  1  AD01-101  BROTHER, BIOLOGICAL  PRIMARY DIAGNOSIS  Alzheimer's Disease  2011-03-15  1995-07 
4  ABC123  APMH  AP_04  1  AD01-101  GRANDMOTHER, BIOLOGICAL  PRIMARY DIAGNOSIS  Alzheimer's Disease  2011-03-15  1940-07 
5  ABC123  APMH  AP_05  1  AD01-102  MOTHER, BIOLOGICAL  PRIMARY DIAGNOSIS  Alzheimer's Disease  2011-03-19  1987-01 
6  ABC123  APMH  AP_06  1  AD01-102  FATHER BIOLOGICAL  PRIMARY DIAGNOSIS  Mild Cognitive Impairment  2011-03-19  1979-03 
7  ABC123  APMH  AP_07  1  AD01-102  GRANDFATHER, BIOLOGICAL  PRIMARY DIAGNOSIS  Alzheimer's Disease  2011-03-19  1945-03 
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3  Disease Assessments 
3.1 Cerebrospinal Fluid Sampling 
Cerebrospinal Fluid (CSF) sampling has been identified as an important source of biomarkers as covariates in Alzheimer’s disease. The primary biomarkers of 
interest obtained from these samples include β-amyloid 1-42 (commonly known as Aβ or “Abeta”), tau protein (total), and the phosphorylated form of tau 
protein. These three markers have been implicated in the pathogenesis of Alzheimer’s and Alzheimer’s-related dementias. Characterizing a subject’s Abeta and 
tau burden can therefore contribute to the understanding of his or her disease. In this section, we cover how to represent the data generated throughout the 
process, from sample collection via lumbar puncture (spinal tap), through the aliquoting and storage of the sample, ending with the generation of the results. 
 
It is important to note that several factors of the sample collection methods may affect the results, and therefore should be tightly controlled and recorded. For 
example, it is possible for Abeta and tau proteins in a CSF sample to react with the material of the sample collection tube, producing differing results in the 
downstream processing of the same sample if the sample were to be split into two tubes of differing composition. The CSF sample processing examples shown in 
this guide address this issue from a data standards perspective that shows how to represent the details of these processes in SDTM so that analysts have the 
necessary information available to interpret the results. 
 
The following concept map shows the provenance of a CSF biomarker value (represented in the LB domain), starting with the generation of the CSF sample via 
lumbar puncture, then following through the various events the sample may go through (aliquoting, freezing, thawing) in the process of generating actual 
endpoints. Each step along the process shows at a high-level the different types of data generated that should be represented.  
 
Dashed lines point to the corresponding SDTM domains (or groups of domains, such as those for devices) in which the data generated are submitted. Refer to the 
individual domains referenced in the concept map below for a detailed view of how the datasets should be populated using more detailed, realistic example 
values showing β-amyloid, tau, and phosphorylated tau as endpoints. Dashed lines lead to the corresponding SDTM domains in which the data generated are 
represented. The red lines indicate steps in the process that may occur in differing order: once collected, samples may be processed immediately, or frozen for 
processing later.  
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Figure 3.1: CSF Sampling and Processing 
 
3.1.1 Relating Records in CSF Sampling 
CSF sampling begins with a lumbar puncture, represented in the Procedures (PR) domain. The origin of the CSF sample in the Biospecimen Events (BE) domain 
is linked to the lumbar puncture via the REFID variable: PRREFID=BEREFID when BECAT=COLLECTION.  
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From this point, the CSF sample is usually aliquoted. Each aliquot is assigned a PARENT value that corresponds to the REFID value of the collected sample, 
thus identifying the aliquot as a “child” of that sample. Additionally, each aliquot would be assigned a unique REFID value that may be based on the REFID of 
the parent. For example, if the PRREFID/BEREFID for the sample collection is 100, then BEREFID for the first aliquoting event could be 100.1, and so on. 
From this point on, all other events and findings using the sample aliquot will be assigned a REFID value in those subsequent domains corresponding to the 
unique REFID for the aliquot used. In this way, the REFID values can be viewed as a unique sample ID across all observations recorded on that sample in 
subsequent domains.  
 
The SPDEVID variable is used to identify devices associated with events or findings in other domains. In the PR domain record for Lumbar Puncture, it 
identifies the spinal needle used to draw the sample. In the biospecimen domains (BE/BS), it identifies the tube lots used to collect/store the sample and aliquots; 
it may also be used to represent a separate device identifier for a freezer used for storage when freezing is represented in BE. SPDEVID in the LB domain 
identifies the 96-well plate used to obtain the ultimate endpoint represented in that domain. All SPDEVID values also match their respective device identifiers 
and properties represented in the device domains. 
 
Figure 3.1.1: Relating Records in CSF Sampling 
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3.1.2 Examples for CSF Sampling 
The example below uses domains and variables that are not final at the time of the publication of this document. For additional assumptions, see Appendix C. 
 
Example 
This example is organized to reflect the stages of CSF sampling and processing, from collection to results, followed by ancillary device information and dataset 
relationships.  
 
Because a lumbar puncture may result in adverse events, it is represented in the Procedures (PR) domain.  
 
The location of the procedure is noted in PRLOC. The start and end time are noted also. PRREFID will match BEREFID when BECAT=COLLECTION. 
SPDEVID identifies the spinal needle used to extract the sample. Fasting status (--FAST) is a variable expected to be added to Interventions in SDTM 1.4, and is 
of special interest for AD studies.  
 
Row 1:   The subject was fasting at the time as indicated by PRFAST=Y. 
 
pr.xpt 
Row  STUDYID  DOMAIN  USUBJID  SPDEVID  PRSEQ  PRREFID  PRTRT  PRLOC  PRFAST  PRSTDTC  PRENDTC 
1  ABC123  PR  AD01-101  23290  1  100  Lumbar Puncture  L3-L4 INTERVERTEBRAL SPACE  Y  2013-05-22T08:15:00  2013-05-22T08:50:00 
 
Because the lumbar puncture is results in a specimen collection, it is also represented in the Biospecimen Event (BE) domain, along with similar information 
about biospecimen-related events, such as aliquoting or freezing.  
 
For Alzheimer’s disease studies, each sample needs a separate identifier to link it to further actions or characteristics of the sample. Therefore, each aliquoting 
event is assigned a unique BEREFID value that can be traced to the BEREFID assigned for the collected “parent” sample. BEREFID is used to connect the BE 
and BS (BSREFID) domains, as well as to any results in the LB domain (LBREFID) obtained from the sample.  
 
In this example, one aliquot was thawed and returned to the freezer later. That particular aliquot can be traced through to the LB domain where biomarker test 
results are represented. For ease of reviewing the example, not all of the detailed rows are shown. These rows have “…” in them. For example, what would have 
been Rows 6-19 are represented by one row and use the “…” notation. In these rows, only the values for BESEQ and BEREFID change with regard to Row 5.  
 
Row 1:  Shows the origin of the specimen (BETERM when BECAT=COLLECTION). Note that BEREFID=100, which matches the PRREFID in PR.xpt 
above.  
Rows 2-20:   Show that the sample was aliquoted. Each separate aliquot is assigned a unique BEREFID. In this case, BEREFID is an incremented decimal value 
based on the original sample using BEREFID when BECAT=COLLECTION as a base number. This is not an explicit requirement, but makes 
tracking the samples easier. The definitive link between parent-child samples is defined by the PARENT variable shown in the BS domain. 
SPDEVID refers to the tube storing the aliquot.  
Rows 21-39:  Show that each aliquot was frozen. BEREFID identifies an individual aliquot. SPDEVID refers to the freezer storing the aliquot.  
Rows 40-41:   Show an aliquot (BEREFID) that was thawed for analysis then the remainder was re-frozen. Note that the start and end times (BESTDTC, 
BEENDTC) of the thawing event define the amount of time the sample spent out of the freezer.  
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be.xpt 
Row STUDYID DOMAIN USUBJID SPDEVID BESEQ BEREFID  BETERM  BEDECOD  BECAT  BEDTC  BESTDTC  BEENDTC 
1  ABC123  BE  AD01-101  23290  1  100  Lumbar Puncture LUMBAR PUNCTURE COLLECTION  2013-05-22  2013-05-22T08:15:00  2013-05-22T08:50:00 
2  ABC123  BE  AD01-101  9330  2  100.1  Aliquoted  ALIQUOTED  PREP  2013-05-22  2013-05-22T09:00:00   
3  ABC123  BE  AD01-101  9330  3  100.2  Aliquoted  ALIQUOTED  PREP  2013-05-22  2013-05-22T09:00:00   
4  ABC123  BE  AD01-101  9330  4  100.3  Aliquoted  ALIQUOTED  PREP  2013-05-22  2013-05-22T09:00:00   
5  ABC123  BE  AD01-101  9330  5  100.4  Aliquoted  ALIQUOTED  PREP  2013-05-22  2013-05-22T09:00:00   
…  …  …  …  …  …  …  …  …  …  …  …  … 
20  ABC123  BE  AD01-101  9330  20  100.19  Aliquoted  ALIQUOTED  PREP  2013-05-22  2013-05-22T09:00:00   
21  ABC123  BE  AD01-101  31  21  100.1  Frozen  FROZEN  PREP  2013-05-22  2013-05-22T09:11:00   
22  ABC123  BE  AD01-101  31  22  100.2  Frozen  FROZEN  PREP  2013-05-22  2013-05-22T09:11:00   
23  ABC123  BE  AD01-101  31  23  100.3  Frozen  FROZEN  PREP  2013-05-22  2013-05-22T09:11:00   
24  ABC123  BE  AD01-101  31  24  100.4  Frozen  FROZEN  PREP  2013-05-22  2013-05-22T09:11:00   
…  …  …  …  …  …  …  …  …  …  …  …  … 
39  ABC123  BE  AD01-101  31  39  100.19  Frozen  FROZEN  PREP  2013-05-22  2013-05-22T09:11:00   
40  ABC123  BE  AD01-101  31  40  100.2  Thawed  THAWED  PREP  2013-05-23  2013-05-23T08:00:00  2013-05-23T08:18:00 
41  ABC123  BE  AD01-101  31  41  100.2  Frozen  FROZEN  PREP  2013-05-23  2013-05-23T08:18:00   
 
Findings data captured during specimen collection, preparation, and handling are represented in the Biospecimen (BS) domain. Note that BS is a draft domain, 
and the mechanism by which records are related may change. 
 
For ease of use in review, not all of the detailed rows are shown. These rows have “…” in them. For example, Rows 4-19 are represented by one row and use the 
“…” notation. In these rows, only the values for BSSEQ and BSREFID change with regards to Row 3.  
 
Row 1:  Shows the total volume of cerebrospinal fluid collected during the lumbar puncture by using the same values for BSREFID and BEREFID. 
SPDEVID refers to the lot of tubes used to store the sample. This is the parent (collected) sample from which further aliquots were generated, so 
BSSPCLVL=1 
Rows 2-20:  Show the volume of each aliquot created. SPDEVID refers to the lot of tubes used to store the aliquot. BSPARENT for these records is set equal to 
the BSREFID of the sample shown in Row 1, indicating that the parent sample from which these aliquots were obtained is the 20-mL sample 
shown in that row. Additionally BSSPCLVL=2 for these rows since these samples are second generation samples generated from the parent sample 
whose specimen level is 1.  
Row 21:   Shows the remaining volume of aliquot 2 (REFID=100.2) that was thawed, partially used for analysis, and then re-frozen. 
 
bs.xpt  
Row  STUDYID  DOMAIN  USUBJID  SPDEVID  BSSEQ  BSREFID  BSTESTCD  BSTEST  BSCAT  BSORRES  BSORRESU  BSSTRESC 
1  ABC123  BS  AD01-101  8842  1  100  VOLUME  Volume  SPECIMEN MEASUREMENT  20  mL  20 
2  ABC123  BS  AD01-101  9330  2  100.1  VOLUME  Volume  SPECIMEN MEASUREMENT  2  mL  2 
3  ABC123  BS  AD01-101  9330  3  100.2  VOLUME  Volume  SPECIMEN MEASUREMENT  1  mL  1 
…  …  …  …  …  …  …  …  …  …  …  …  … 
20  ABC123  BS  AD01-101  9330  20  100.19  VOLUME  Volume  SPECIMEN MEASUREMENT  1  mL  1 
21  ABC123  BS  AD01-101  9330  21  100.2  VOLUME  Volume  SPECIMEN MEASUREMENT  0.5  mL  0.5 
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Row  BSSTRESN  BSSTRESU  BSSPEC  BSPARENT   BSSPCLVL   BSDTC 
1 (cont)  20  mL  CEREBROSPINAL FLUID    1  2013-05-22 
2 (cont)  2  mL  CEREBROSPINAL FLUID  100  2  2013-05-22 
3 (cont)  1  mL  CEREBROSPINAL FLUID  100  2  2013-05-22 
…  …  …  …  …  …  … 
20 (cont)  1  mL  CEREBROSPINAL FLUID  100  2  2013-05-22 
21 (cont)  0.5  mL  CEREBROSPINAL FLUID  100  2  2013-05-23 
 
Results from laboratory tests performed on aliquoted samples are represented in the LB domain.  
 
Rows 1-3:  Show results for three tests. These results are the second Aliquot of sample 100, as indicated by the value 100.2 in LBREFID. SPDEVID indicates 
that these tests were done with device 14690. The DI domain has the information that this device is a triplex plate (i.e., a plate containing probes 
for each of these three biomarkers). 
 
lb.xpt 
Row STUDYID  DOMAIN  USUBJID  SPDEVID LBSEQ  LBREFID LBTESTCD  LBTEST  LBCAT  LBORRES  LBORRESU  LBORNRLO  LBORNRHI 
1  ABC123  LB  AD01-101  14690  1  100.2  AMYLB42  Amyloid Beta 42  BIOMARKER  400  pg/mL  450  1000 
2  ABC123  LB  AD01-101  14690  2  100.2  TPROT  Tau Protein  BIOMARKER  800  pg/mL  125  400 
3  ABC123  LB  AD01-101  14690  3  100.2  TPROTP  Phosphorylated Tau Protein BIOMARKER  120  pg/mL  1  70 
 
Row  LBSTRESC  LBSTRESN  LBSTRESU  LB SPEC  LBBLFL  VISITNUM  LBDTC 
1 (cont)  400  400  pg/mL  CSF  Y  1  2013-05-22 
2 (cont)  800  800  pg/mL  CSF  Y  1  2013-05-22 
3 (cont)  120  120  pg/mL  CSF  Y  1  2013-05-22 
 
Data about the devices used throughout are represented in the Device Identifier (DI) domain.  
 
Rows 1-3:  Describe the spinal needle used to extract CSF, the manufacturer and the lot number of the needle.  
Rows 4-6:  Describe the tube lot used to collect the entire volume of CSF, and the manufacturer of the tubes.  
Row 7:  Describes the freezer in which the aliquots were stored. This is important for tracking issues related to potential device failures that may affect 
results.  
Rows 8-10:  Describe the tube lot used to store the aliquots created from the entire volume sample, and the manufacturer of the lot. All aliquots used the same 
tube lot.  
Rows 11-13:  Describe the 96-well plate used to analyze a CSF sample aliquot.  
 
di.xpt 
Row  STUDYID  DOMAIN  SPDEVID  DISEQ  DIPARMCD  DIPARM  DIVAL 
1  ABC123  DI  23290  1  DEVTYPE  Device Type  Atraumatic Spinal Needle 
2  ABC123  DI  23290  2  MANUF  Manufacturer  Acme 
3  ABC123  DI  23290  3  LOT  Lot Number  MRC1028 
4  ABC123  DI  8842  1  DEVTYPE  Device Type  Tube 
5  ABC123  DI  8842  2  MANUF  Manufacturer  Acme 
6  ABC123  DI  8842  3  LOT  Lot Number  1200A 
7  ABC123  DI  31  1  DEVTYPE  Device Type  Freezer 
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Row  STUDYID  DOMAIN  SPDEVID  DISEQ  DIPARMCD  DIPARM  DIVAL 
8  ABC123  DI  9330  1  DEVTYPE  Device Type  Tube 
9  ABC123  DI  9330  2  MANUF  Manufacturer  Acme 
10  ABC123  DI  9330  3  LOT  Lot Number  6500A 
11  ABC123  DI  14690  1  DEVTYPE  Device Type  Plate 
12  ABC123  DI  14690  2  MANUF  Manufacturer  Advantage Biosciences 
13  ABC123  DI  14690  3  LOT  Lot Number  1q02192012 
 
The fixed properties of a device identified in DI are represented in the Device Properties (DO) domain.  
 
Row 1:   Shows the size of the needle used in the lumbar puncture.  
Row 2:   Shows the composition of the tube used to store the aliquots. 
Row 3:   Shows the degree of multiplexing for the 96-well plate. 
Row 4:   Shows the temperature of the freezer listed in the DI domain. Note that by storing temperature info in the DO domain, it is indicated that this 
freezer is a dedicated -80 degrees C freezer. If the freezer had been adjustable, the temperature setting would be listed in the DU domain as per the 
assumptions of these two domains.  
 
do.xpt 
Row  STUDYID  DOMAIN  SPDEVID  DOSEQ  DOTESTCD  DOTEST  DOORRES  DOORRESU 
1  ABC123  DO  23290  1  SIZE  Size  20  GAUGE 
2  ABC123  DO  9330  1  CMPSTN  Composition  Polypropylene   
3  ABC123  DO  14690  1  MULTPLEX  Degree of Multiplexing  Triplex   
4  ABC123  DO  31  1  TEMP  Temperature  -80  C 
 
The RELREC table below shows a number of dataset relationships: 
1.  How an individual biospecimen (aliquot) event is related to multiple laboratory results records. 
2.  How an individual CSF sample obtained from the biospecimen collection is related to the lumbar puncture procedure is related to biospecimen 
collection event for the sample. 
3.  How the multiple biospecimen events in the BE domain are related to the multiple biospecimen properties in the BS domain. 
 
Rows 1-2:  Indicates the link between the biospecimen (aliquot) and the lab result. A unique BEREFID for each aliquot is linked with the same LBREFID 
value to obtain all the LB results related to the individual aliquot. 
Rows 3-4:  Show how to relate records between the procedure and the collection of the sample. This describes that the lumbar procedure with PRREFID=100 
is linked to the BE collection event with BEREFID=100. 
Rows 5-6:   Shows the relationship between biospecimen events and biospecimen properties. Note that in the examples above, most records show a one to one 
relationship (e.g., a volume measurement in BS for each event in BE). However, this relationship can be, and may often be, a many to many 
relationship. This describes the multiple biospecimen events related to the multiple biospecimen tests that are represented by the RELREC MANY 
to MANY relationships between the BEREFID and the BSREFID. This relationship is unusual and challenging to manage in a join/merge and only 
represents the concept of this relationship. To uniquely identify all the BSTESTS related to an individual BETERM, select an individual BEREFID 
to join/merge with the BSREFID to revise this to a ONE to MANY relationship to obtain all related BSTEST results. 
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relrec.xpt 
Row  STUDYID  RDOMAIN  USUBJID  IDVAR  IDVARVAL  RELTYPE  RELID 
1  ABC123  BE     BEREFID     ONE  1 
2  ABC123  LB     LBREFID     MANY  1 
3  ABC123  PR     PRREFID     ONE  2 
4  ABC123  BE     BEREFID     ONE  2 
5  ABC123  BE     BEREFID    MANY  3 
6  ABC123  BS     BSREFID    MANY  3 
 
3.2 Imaging 
Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) or Positron Emission Tomography /Computerized Tomography (PET/CT) are 
valuable tools for assessing imaging biomarkers in AD. The following subsections describe these procedures at a high level, with an emphasis on the data that are 
generated, and how they should be represented in SDTM-based datasets. 
3.2.1 Magnetic Resonance Imaging 
In AD, MRI is primarily used for obtaining volumetric brain measurements including hippocampus volume and total brain volume, as evidence suggests these 
biomarkers correlate with disease progression. In a brain MRI procedure, the subject lies down and is entered into the MRI scanner. Exogenous contrast-
enhancing agents are typically not used in AD. Once the subject is in the scanner, the procedure begins by collecting a series of image slices across the region of 
interest (in this case, the head). Multiple sets of image slices—commonly referred to as scans—are typically collected across the entire volume of the head, with 
each new set (scan) potentially using different properties than the scan before. This is an important fact to be aware of since the changing properties between each 
scan may affect how that image series can be used or interpreted, and is usually controlled by protocol and/or recorded for later reference by analysts. To 
reiterate: a single MRI procedure (as would be represented in the Procedures (PR) domain) results in multiple scans, each differentiated by the set of properties 
that were in place for that scan. These changeable settings that may vary from one scan to the next are represented in the Device In-Use (DU) domain. Examples 
include, but are not limited to, properties such as image weighting, matrix size, slice thickness, repetition time (TR), echo time (TE), inversion time (TI), and 
anatomical plane of image acquisition. These parameters are usually represented in standardized reports such as the DICOM header.  
 
Additionally, MRI scanners have inherent onboard properties which do not change, including properties such as coil strength. These unchanging properties are 
represented in the Device Properties (DO) domain. Finally, information such as make, model, and serial number would be represented in the Device Identifiers 
(DI) domain. 
 
In this section, we show examples of how to represent these types of data in SDTM-based datasets and how to relate them to each other and to the volumetric 
findings represented in the Morphology (MO) domain. The examples below are only intended to illustrate the data modeling of these various properties and 
findings and are not meant to serve as strict requirements nor as an all-inclusive list of the properties and findings which should be provided in a regulatory 
submission. Sponsors should refer to their regulatory agencies/review divisions for guidance on which data should be recorded and submitted as appropriate for 
their individual studies. 
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The following concept map shows the provenance of a brain morphological measurement (such as brain volume or hippocampus volume) starting with the 
generation of the images via MRI and following through to the derivation of the endpoint. Each step along the process shows at a high level the different types of 
data that are generated and how they should be represented. 
 
For ease of reading, only the salient concepts are shown. Refer to the individual domain examples referenced in the concept map below for a detailed view of 
how the datasets should be populated.  
 
 
Figure 3.2.1: MRI Imaging 
 
3.2.1.1  Relating Records in MRI Imaging 
The derivation of morphological endpoints in MRI imaging begins with the imaging procedure, represented in the PR domain. During this procedure, multiple 
scans may be conducted. Each scan is identified by a unique set of properties that apply to the scan, and those properties are grouped in the Device In-Use (DU) 
domain by DUREFID. The link between the findings and the individual scan from which they are derived is maintained by having MOREFID = DUREFID. This 
allows for linking the findings to a unique scan and its associated parameters within the procedure. A single imaging procedure will have a unique PRREFID, but 
each scan conducted during that procedure must be differentiated. For this reason, PRREFID cannot be used to link the procedure directly to the findings (brain 
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volume, etc.) in the MO domain via MOREFID. This direct link between the procedure and any associated findings in MO is maintained by having PRLNKID = 
MOLNKID. SPDEVID in all cases below refers to the unique identifier for the MRI scanner.  
 
Note that in the use cases examined for Alzheimer’s, exogenous contrast reagent administration was not a factor in MRI. If a contrast agent were used, it would 
be placed in the AG domain according to the example shown in the PET imaging example described in Section 3.2.2. 
 
 
Figure 3.2.1.1: Relating Records in MRI Imaging 
 
3.2.1.2  Examples for MRI Imaging 
The example below uses domains and variables which are not final at the time of the publication of this document. For additional assumptions, see Appendix C. 
 
Example 
The example below illustrates the modeling of the various pieces of information collected and generated (as described above) from the MRI procedure through 
the determination of the volumetric results, using the PR, MO, DU, DI, and DO domains. As shown in Figure 3.2.1.1, both --LNKID and --REFID have been 
used to allow MO to be related to two disparate datasets.  
 
The occurrence of an MRI procedure is represented in the PR domain.  
 
Row 1:  Shows an MRI of the head for a subject. PRLNKID links the procedure to the findings in MO via MOLNKID. Note that the subject was fasting 
during this procedure.  
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pr.xpt 
Row  STUDYID  DOMAIN  USUBJID  SPDEVID  PRSEQ  PRLNKID  PRTRT  PRLOC  PRFAST  PRSTDTC 
1  ABC123  PR  AD01-101  16  2  02  MRI  HEAD  Y  2012-05-22T12:30:00 
 
Volumetric endpoints derived from scans during an MRI procedure are represented in the Morphology (MO) domain.  
 
In this example, MOMETHOD indicates that contrast enhancement was not used. If contrast enhancement had been used, MOMETHOD should be set to 
“CONTRAST ENHANCED MRI” in accordance with controlled terminology. MODTC matches the date of the MRI procedure from which these results were 
obtained. MOLNKID matches the PRLNKID for the MRI procedure. 
 
Rows 1-3:  Show measurements for hippocampal volume taken during the MRI. A measurement for left, right, and both sides is included (MOLAT). The 
bilateral measure is the sum of the left and right. MOREFID relates the records back to the properties of the originating scan in the DU domain (via 
DUREFID).  
Row 4:   Shows a cerebral cortex thickness measurement from the same scan shown in Rows 1-3, as indicated by the same value of MOREFID.  
Row 5:   Shows a total brain volume measurement from the same patient, but a different scan (as indicated by a different MOREFID). The properties of this 
scan would also be linked via DUREFID in the DU domain. 
 
mo.xpt 
Row  STUDYID  DOMAIN  USUBJID  SPDEVID  MOSEQ  MOLNKID  MOREFID  MOTESTCD  MOTEST  MOORRES  MOORRESU  MOSTRESC  MOSTRESN  MOSTRESU 
1  ABC123  MO  AD01-101  16  1  02  1234  VOLUME  Volume  1.8  mL  1.8  1.8  mL 
2  ABC123  MO  AD01-101  16  2  02  1234  VOLUME  Volume  1.9  mL  1.9  1.9  mL 
3  ABC123  MO  AD01-101  16  3  02  1234  VOLUME  Volume  3.7  mL  3.7  3.7  mL 
4  ABC123  MO  AD01-101  16  4  02  1234  THICK  Thickness  3  mm  3  3  mm 
5  ABC123  MO  AD01-101  16  5  02  1235  VOLUME  Volume  864  mL  864  864  mL 
 
Row  MOLOC  MOLAT  MOMETHOD  MOANMETH  MODTC 
1 (cont)  HIPPOCAMPUS  RIGHT  MRI WITHOUT CONTRAST  SOFTWARE ANAYLSIS  2012-05-22 
2 (cont)  HIPPOCAMPUS  LEFT  MRI WITHOUT CONTRAST  SOFTWARE ANAYLSIS  2012-05-22 
3 (cont)  HIPPOCAMPUS  BILATERAL  MRI WITHOUT CONTRAST  SOFTWARE ANAYLSIS  2012-05-22 
4 (cont)  CEREBRAL CORTEX    MRI WITHOUT CONTRAST  SOFTWARE ANAYLSIS  2012-05-22 
5 (cont)  BRAIN    MRI WITHOUT CONTRAST  SOFTWARE ANAYLSIS  2012-05-22 
 
Because two devices are used in the MRI procedure, the MRI device is represented in SPDEVID, while the analysis software used is represented using a 
Supplemental Qualifiers dataset. This method is under review by the CDISC standards review council (SRC) and should not be considered final or definitive. 
Future decisions by SRC may require recording the analysis software as a device as well. 
 
suppmo.xpt 
Row  STUDYID  RDOMAIN  USUBJID  IDVAR  IDVARVAL  QNAM  QLABEL  QVAL 
1  ABC123  MO  AD01-101  MOSEQ  1  SFTWR  Analysis Software  Neuroquant 
2  ABC123  MO  AD01-101  MOSEQ  1  SFTWRVER  Software Version  12.1 
3  ABC123  MO  AD01-101  MOSEQ  2  SFTWRE  Analysis Software  Neuroquant 
4  ABC123  MO  AD01-101  MOSEQ  2  SFTWRVER  Software Version  12.1 
5  ABC123  MO  AD01-101  MOSEQ  3  SFTWR  Analysis Software  Neuroquant 
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Row  STUDYID  RDOMAIN  USUBJID  IDVAR  IDVARVAL  QNAM  QLABEL  QVAL 
6  ABC123  MO  AD01-101  MOSEQ  3  SFTWRVER  Software Version  12.1 
7  ABC123  MO  AD01-101  MOSEQ  4  SFTWR  Analysis Software  Neuroquant 
8  ABC123  MO  AD01-101  MOSEQ  4  SFTWRVER  Software Version  12.1 
9  ABC123  MO  AD01-101  MOSEQ  5  SFTWR  Analysis Software  Freesurfer 
10  ABC123  MO  AD01-101  MOSEQ  5  SFTWRVER  Software Version  4.0.2 
 
The MRI imaging device used, the manufacturer, and the model are represented in the DI domain. Because SPDEVID is included as a variable in the other 
datasets, RELREC is not needed to relate DI to other domains.  
 
di.xpt 
Row  STUDYID  DOMAIN  SPDEVID  DISEQ  DIPARMCD  DIPARM  DIVAL 
1  ABC123  DI  16  1  DEVTYPE  Device Type  MRI 
2  ABC123  DI  16  2  MANUF  Manufacturer  GE 
3  ABC123  DI  16  3  MODEL  Model  SIGNA 
 
Changeable properties and parameters for devices identified in DI are represented in the Device In-Use (DU) domain.  
 
The example below shows how to represent various properties of the MRI device that may change between scans. DUREFID indicates a unique scan, as defined 
by a changeable set of properties that were set as indicated for each scan. Note that the properties in this example are meant to serve as examples only of 
properties that could appear in a DICOM header. Sponsors should refer to FDA guidance and speak to their individual review division(s) to determine which 
parameters should be included in the data submission, and then verify if controlled terminology exists for these parameters. New terminology for the DUTEST 
and DUTESTCD code lists can be requested through the new term request process at NCI EVS.  
 
Rows 1-16:   This particular scan was conducted in the sagittal plane, using the MRI scanner represented by SPDEVID=16. 
Rows 17-32:  This particular scan was conducted in the transverse plane. This represents the second scan conducted on the same subject during the same imaging 
procedure that started with the scan depicted in rows 1-16. The only property that has changed for this scan from the previous scan is represented 
in DUTEST=Anatomical Plane.  
 
du.xpt 
Row STUDYID DOMAIN USUBJID SPDEVID DUSEQ DUREFID DUTESTCD  DUTEST  DUORRES  DUORRESU … VISITNUM  DUDTC 
1  ABC123  DU  AD01-101  16  1  1234  ANTPLANE  Anatomical Plane  SAGITTAL    …  1  2012-05-22T12:30:00 
2  ABC123  DU  AD01-101  16  2  1234  PULSSEQ  Pulse Sequence  SPGR    …  1  2012-05-22T12:30:00 
3  ABC123  DU  AD01-101  16  3  1234  STHICK  Slice Thickness  4  mm  …  1  2012-05-22T12:30:00 
4  ABC123  DU  AD01-101  16  4  1234  AQMTRXSZ  Image Acquisition Matrix Size  256X256    …  1  2012-05-22T12:30:00 
5  ABC123  DU  AD01-101  16  5  1234  WEIGHTNG  Weighting  T1    …  1  2012-05-22T12:30:00 
6  ABC123  DU  AD01-101  16  6  1234  INTSPACE  Interslice Spacing  1  mm  …  1  2012-05-22T12:30:00 
7  ABC123  DU  AD01-101  16  7  1234  FLDVIEW  Field of View  280X280  mm  …  1  2012-05-22T12:30:00 
8  ABC123  DU  AD01-101  16  8  1234  SFTWRVER  Software Version  3.1    …  1  2012-05-22T12:30:00 
9  ABC123  DU  AD01-101  16  9  1234  FLIPANGL  Flip Angle  8  deg  …  1  2012-05-22T12:30:00 
10  ABC123  DU  AD01-101  16  10  1234  PIXSPCX  Pixel Spacing X  1.25  mm  …  1  2012-05-22T12:30:00 
11  ABC123  DU  AD01-101  16  11  1234  PIXSPCY  Pixel Spacing Y  1.25  mm  …  1  2012-05-22T12:30:00 
12  ABC123  DU  AD01-101  16  12  1234  INVRTIME  Inversion Time  1000  msec  …  1  2012-05-22T12:30:00 
13  ABC123  DU  AD01-101  16  13  1234  ECHOTIME  Echo Time  3.59  msec  …  1  2012-05-22T12:30:00 
14  ABC123  DU  AD01-101  16  14  1234  REPTIME  Repetition Time  3000  msec  …  1  2012-05-22T12:30:00 
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Row STUDYID DOMAIN USUBJID SPDEVID DUSEQ DUREFID DUTESTCD  DUTEST  DUORRES  DUORRESU … VISITNUM  DUDTC 
15  ABC123  DU  AD01-101  16  15  1234  NUMSLICE  Number of Slices  125    …  1  2012-05-22T12:30:00 
16  ABC123  DU  AD01-101  16  16  1234  IMAQDIM  Image Acquisition Dimensionality  3D    …  1  2012-05-22T12:30:00 
17  ABC123  DU  AD01-101  16  17  1235  ANTPLANE  Anatomical Plane  TRANSVERSE    …  1  2012-05-22T12:50:00 
18  ABC123  DU  AD01-101  16  18  1235  PULSSEQ  Pulse Sequence  SPGR    …  1  2012-05-22T12:50:00 
19  ABC123  DU  AD01-101  16  19  1235  STHICK  Slice Thickness  4  mm  …  1  2012-05-22T12:50:00 
20  ABC123  DU  AD01-101  16  20  1235  AQMTRXSZ  Image Acquisition Matrix Size  256X256  Pixels  …  1  2012-05-22T12:50:00 
21  ABC123  DU  AD01-101  16  21  1235  WEIGHTNG  Weighting  T1    …  1  2012-05-22T12:50:00 
22  ABC123  DU  AD01-101  16  22  1235  INTSPACE  Interslice Spacing  1  mm  …  1  2012-05-22T12:50:00 
23  ABC123  DU  AD01-101  16  23  1235  FLDVIEW  Field of View  280X280  mm  …  1  2012-05-22T12:50:00 
24  ABC123  DU  AD01-101  16  24  1235  SFTWRVER  Software Version  3.1    …  1  2012-05-22T12:50:00 
25  ABC123  DU  AD01-101  16  25  1235  FLIPANGL  Flip Angle  8  deg  …  1  2012-05-22T12:50:00 
26  ABC123  DU  AD01-101  16  26  1235  PIXSPCX  Pixel Spacing X  1.25  mm  …  1  2012-05-22T12:50:00 
27  ABC123  DU  AD01-101  16  27  1235  PIXSPCY  Pixel Spacing Y  1.25  mm  …  1  2012-05-22T12:50:00 
28  ABC123  DU  AD01-101  16  28  1235  INVRTIME  Inversion Time  1000  msec  …  1  2012-05-22T12:50:00 
29  ABC123  DU  AD01-101  16  29  1235  ECHOTIME  Echo Time  3.59  msec  …  1  2012-05-22T12:50:00 
30  ABC123  DU  AD01-101  16  30  1235  REPTIME  Repetition Time  3000  msec  …  1  2012-05-22T12:50:00 
31  ABC123  DU  AD01-101  16  31  1235  NUMSLICE  Number of Slices  125    …  1  2012-05-22T12:50:00 
32  ABC123  DU  AD01-101  16  32  1235  IMAQDIM  Image Acquisition Dimensionality  3D    …  1  2012-05-22T12:50:00 
 
Fixed properties for the MRI scanner used are represented in the DO domain.  
 
do.xpt 
Row  STUDYID  DOMAIN  SPDEVID  DOSEQ  DOTESTCD  DOTEST  DOORRES  DOORRESU 
1  ABC123  DO  16  1  COILTYPE  Coil Type  Head   
2  ABC123  DO  16  2  COILSTR  Coil Strength  1.5  T 
 
The relationship between the MRI scan and the results, and the relationship between the results and the settings of the MRI device, are represented in RELREC.  
 
Rows 1-2:  Link the morphology result to the particular procedure performed. This indicates that the PRLNKID variable for an individual procedure is linked 
to multiple MO records via the same value in the MOLNKID variable. 
Rows 3-4:  Link the morphology result to the particular scan and properties/settings of the scanner. This describes the multiple MO results that are related to 
multiple DUTESTs that are represented by the RELREC MANY to MANY relationships between the MOREFID and the DUREFID. This 
relationship is unusual and challenging to manage in a join/merge and only represents the concept of this relationship. To uniquely identify all the 
DUTESTS related to an individual MOTEST, first select an individual MOREFID to join/merge with the DUREFID to revise this to a ONE to 
MANY relationship to obtain all related DUTEST results. 
 
relrec.xpt 
Row  STUDYID  RDOMAIN  USUBJID  IDVAR  IDVARVAL  RELTYPE  RELID 
1  ABC123  PR     PRLNKID    ONE  5 
2  ABC123  MO     MOLNKID    MANY  5 
3  ABC123  MO     MOREFID    MANY  4 
4  ABC123  DU     DUREFID    MANY  4 
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3.2.2 Positron Emission Tomography Imaging 
Unlike the volumetric MRI imaging described in Section 3.2.1, PET imaging is used to characterize functional processes in the brain. In AD, it is used to 
quantify amyloid plaques and to assess glucose metabolism. PET imaging requires the intravenous administration of a radiopharmaceutical, or radiolabeled 
“tracer,” to the subject in order to target the region of interest for imaging. Tracers are specific to the processes they are designed to characterize. A tracer 
designed for amyloid plaque imaging would not work for assessment of glucose metabolism, nor vice versa. These tracers are molecules designed to be taken up 
by or bind to specific regions of the brain and contain a radioactive element. When the tracer accumulates in the region it is designed to bind, the radioactive 
signal emitted from this region rises relative to the signal emitted from regions it is not designed to bind. PET scanners are designed to collect the radioactivity 
emitted and localize this signal to the region where it has accumulated. These tracers require a specific uptake time—the time from when they were administered 
to the subject to when the imaging procedure can begin—in order to ensure time is given for them to accumulate at their target location in the brain. Consistent 
uptake times are required to ensure comparability of results across subjects and visits within a given protocol. These tracers are represented in the Procedure 
Agents (AG) domain. It is important to record the start time of tracer administration, as well as the start time of the imaging procedure (represented, as in the 
MRI examples, in the PR domain). This ensures analysts can determine if uptake time was comparable across observations.  
 
Once the specified uptake time has passed, the patient is entered into the PET scanner, and the imaging procedure begins. As in MRI, a single PET procedure 
may result in multiple scans. As in the MRI examples, the set of changeable properties that define a scan are grouped in the DU domain, and linked to the 
findings in the NV domain, by using the same --REFID value. PET scanners also have unchanging properties and identifiers analogous to MRI scanners, which 
are represented in the DO and DI domains, respectively, as described in Section 3.2.1.  
 
The ultimate endpoint generated by a PET procedure comes in the form of a Standard Uptake Value Ratio (SUVR). SUVR is a ratio of the signal coming from 
the brain region of interest (to which the tracer is designed to target) compared to the signal emitted from some reference region in the brain. Reference regions 
are chosen based on the likelihood that the tracer will not be taken up significantly in that region, and thus they serve as a background signal for normalization. 
Since SUVR is a surrogate measurement for some functional activity, as opposed to a mere structural (morphological) measurement as in the case of volumetric 
MRI endpoints, these results are represented in the Nervous System Findings (NV) domain.  
 
The anatomical data provided by PET scanners are often not sufficient to localize the radioactivity they are designed to image to the level of specificity desired 
by investigators. For this reason, PET scans are often conducted concurrently with CT scans, which allow co-registration of more detailed anatomical data with 
the SUVR data obtained from the PET portion of the image. This is performed concurrently in a single procedure using a hybrid PET/CT scanner. In the use 
cases examined for this guide, the CT portion of the image was used solely for the purpose of anatomical co-registration of the PET data from which the 
endpoints of interest were obtained. Therefore, specific properties of the CT portion of the scans are not represented in the device domains in this guide. 
However, the use of a hybrid PET/CT scanner should be represented in the device type value of the DI domain, and as the method value in the NV domain. 
 
It is important to realize that SUVR is based on quantifying regions of signal in a series of images. The only things that differentiate one SUVR from the next are 
the region of interest and the radiolabeled tracer used. It is therefore essential to record the region of interest and represent this in the NVLOC variable. 
Associated qualifiers of NVLOC (NVLAT, NVDIR) may be used where appropriate. It is also essential to maintain the link between the SUVR value (in the NV 
domain) and the tracer that produced it (in the AG domain).  
 
In the following examples, we demonstrate how to represent these types of data in SDTM-based datasets, and how to maintain and represent the relationship 
between the tracer administration, the PET procedure, the individual scan properties, and the SUVR findings represented in the NV domain.  The examples 
below are only intended to illustrate the data modeling of these various properties and findings, and are not meant to serve as strict requirements or an all-
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inclusive list of the properties and findings which should be provided in a regulatory submission. Sponsors should refer to their regulatory agencies/review 
divisions for guidance on which data should be recorded and submitted as appropriate to their individual protocol(s). 
 
The following concept map shows the provenance of a brain physiological or functional measurement (measured as SUVR, represented in the NV domain) of 
various PET tracers. The process starts with the administration of the radiopharmaceutical, followed by the acquisition of images, and ultimately, the derivation 
of the endpoint. Each step along the process shows in high-level detail the different types of data generated that should be represented.  
Dashed lines lead to the corresponding SDTM domains in which the data generated are represented.  
 
For ease of reading, only the salient concepts are shown. Refer to the individual domain examples referenced in the concept map below for detailed views of how 
the datasets should be populated.  
 
Figure 3.2.2: PET Imaging 
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3.2.2.1  Relating Records in PET Imaging 
Similar to MRI imaging, PET imaging begins with the imaging procedure, represented in the PR domain. The structure and relationships of the data generated 
are handled exactly as in the MRI example, except that the findings are functional or physiological, not morphological, and are therefore represented in the NV 
domain. Furthermore, all PET use cases examined involved the administration of a radiolabeled tracer, which is represented in the AG domain. In these cases, the 
LNKID variable serves as a three-way link between the procedure, the tracer administration, and the results. It is particularly important to maintain the link 
between AGLNKID and NVLNKID as the tracer information in the AG domain describes the target biomarker being imaged, and on which the SUVR in the NV 
domain is based. Note that this approach would also work for MRI use cases that involve an exogenous contrast-agent administration. In the PET and PET/CT 
examples discussed, SPDEVID refers to the PET or PET/CT scanner used. 
 
 
Figure 3.2.2.1: Relating Records in PET Imaging 
 
3.2.2.2  Examples for PET Imaging 
The example below uses domains and variables that are not final at the time of the publication of this document. For additional assumptions, see Appendix C.  
 
Example 
This example shows the modeling of the various pieces of information collected and generated (as described above) from three separate PET or PET/CT 
procedures, each for a separate subject. Two procedures (for subjects AD01-101 and AD01-102) showcase amyloid imaging using two different tracers 
(florbetapir and 11C-PiB), while the third (for subject AD01-103) shows glucose-metabolism imaging using FDG as the tracer. Data include the procedure 
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records in the PR domain, the administration of the tracer in the AG domain, the SUVR endpoints in the NV domain, and the various device properties in the 
respective domains. All subjects were fasting at the time of the procedures as indicated by PRFAST=Y. SPDEVID identifies the scanner used in the procedure. 
  
 
 
Occurrences of PET or PET/CT procedures are recorded in the PR domain.  
 
Rows 1-2:  Show PET/CT head scans for two subjects using the same PET/CT scanner, as defined in SPDEVID. 
Row 3:  Shows a PET scan of the head for a third subject. 
 
pr.xpt 
Row STUDYID DOMAIN USUBJID SPDEVID PRSEQ  PRLNKID  PRTRT  PRLOC  PRFAST  PRSTDTC 
1  ABC123  PR  AD01-101  22  1  03  PET/CT  HEAD  Y  2012-05-22T09:30:00 
2  ABC123  PR  AD01-102  22  1  04  PET/CT  HEAD  Y  2012-05-22T08:00:00 
3  ABC123  PR  AD01-103  44  1  05  PET  HEAD  Y  2012-05-22T09:00:00 
 
Data about the administration of procedure agents such as a radiopharmaceutical tracer for PET or PET/CT scans are represented in the Procedure Agents (AG) 
domain.  
 
Rows 1-3:   Show timing and dosage for tracer substances injected during a PET scan. This relationship is shown in the RELREC table. In this example, 
AGCAT is used to group tracers with the same target. 
 
ag.xpt 
Row  STUDYID  DOMAIN  USUBJID  AGSEQ  AGLNKID  AGTRT  AGCAT  AGDOSE  AGDOSEU  AGSTDTC 
1  ABC123  AG  AD01-101  1  03  18F-Florbetapir   AMYLOID TRACER  370  MBq  2012-05-22T08:40:00 
2  ABC123  AG  AD01-102  1  04  11C-PiB  AMYLOID TRACER  370  MBq  2012-05-22T07:20:00 
3  ABC123  AG  AD01-103  1  05  FDG  GLUCOSE TRACER  400  MBq  2012-05-22T08:30:00 
 
Data about the nervous system physiology or metabolism, such as measured by PET imaging, are represented in the Nervous System Findings (NV) domain.  
 
This example shows measures for standard uptake value ratios taken from three PET scans. SPDEVID shows the scanner used. NVLNKID can be used to link 
back to the imaging procedure record in the PR domain (PRLNKID), as well as to the tracer administration record in the AG domain (AGLNKID). AGLNKID 
would be used to determine which tracer uptake is being measured (SUVR), and therefore to which biomarker the findings pertain. NVDTC corresponds to the 
date of the PET or PET/CT procedure from which these results were obtained.  
 
Rows 1-2:   Show the Standard Uptake Value Ratio (SUVR) findings based on a PET/CT scan for subject AD01-101.  
Rows 3-4:  Show the SUVR findings based on a PET/CT scan for subject AD01-102. 
Rows 5-6:  Show the SUVR findings based on an FDG-PET scan for subject AD AD01-103. 
 
nv.xpt 
Row  STUDYID  DOMAIN  USUBJID  SPDEVID  NVSEQ  NVREFID  NVLNKID  NVTESTCD  NVTEST  NVORRES  NVORRESU 
1  ABC123  NV  AD01-101  22  1  1236  03  SUVR  Standard Uptake Value Ratio  .95  RATIO 
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Row  STUDYID  DOMAIN  USUBJID  SPDEVID  NVSEQ  NVREFID  NVLNKID  NVTESTCD  NVTEST  NVORRES  NVORRESU 
2  ABC123  NV  AD01-101  22  2  1236  03  SUVR  Standard Uptake Value Ratio  1.17  RATIO 
3  ABC123  NV  AD01-102  22  1  1237  04  SUVR  Standard Uptake Value Ratio  1.21  RATIO 
4  ABC123  NV  AD01-102  22  2  1237  04  SUVR  Standard Uptake Value Ratio  1.78  RATIO 
5  ABC123  NV  AD01-103  44  1  1238  05  SUVR  Standard Uptake Value Ratio  1.52  RATIO 
6  ABC123  NV  AD01-103  44  2  1238  05  SUVR  Standard Uptake Value Ratio  1.63  RATIO 
 
Row  NVSTRESC  NVSTRESN  NVSTRRESU  NVLOC  NVDIR  NVMETHOD  NVDTC 
1 (cont)  .95  .95  RATIO  PRECUNEUS    PET/CT SCAN  2012-05-22 
2 (cont)  1.17  1.17  RATIO  CINGULATE CORTEX  POSTERIOR  PET/CT SCAN  2012-05-22 
3 (cont)  1.21  1.21  RATIO  PRECUNEUS    PET/CT SCAN  2012-05-22 
4 (cont)  1.78  1.78  RATIO  CINGULATE CORTEX  POSTERIOR  PET/CT SCAN  2012-05-22 
5 (cont)  1.52  1.52  RATIO  PRECUNEUS    FDGPET  2012-05-22 
6 (cont)  1.63  1.63  RATIO  CINGULATE CORTEX  POSTERIOR  FDGPET  2012-05-22 
 
A Supplemental Qualifiers dataset is needed for additional data elements that are not part of the NV domain. 
 
Rows 1-6:   Shows the reference region used for the SUVR tests shown in the NV domain.  
suppnv.xpt 
Row  STUDYID  RDOMAIN  USUBJID  IDVAR  IDVARVAL  QNAM  QLABEL  QVAL 
1  ABC123  NV  AD01-101  NVSEQ  1  REFREG  Reference Region  CEREBELLUM 
2  ABC123  NV  AD01-101  NVSEQ  2  REFREG  Reference Region  CEREBELLUM 
3  ABC123  NV  AD01-102  NVSEQ  1  REFREG  Reference Region  CEREBELLUM 
4  ABC123  NV  AD01-102  NVSEQ  2  REFREG  Reference Region  CEREBELLUM 
5  ABC123  NV  AD01-103  NVSEQ  1  REFREG  Reference Region  PONS VAROLII 
6  ABC123  NV  AD01-103  NVSEQ  2  REFREG  Reference Region  PONS VAROLII 
 
Data about the devices used throughout are represented in the DI domain.  
 
Rows 1-3: Describe the PET/CT imaging device used in the Amyloid Tracer examples shown in the NV domain.  
Rows 4-6: Describe the PET imaging device used in the Glucose Tracer (FDG) example shown in the NV domain. 
 
di.xpt 
Row  STUDYID  DOMAIN  SPDEVID  DISEQ  DIPARMCD  DIPARM  DIVAL 
1  ABC123  DI  22  1  DEVTYPE  Device Type  PET/CT 
2  ABC123  DI  22  2  MANUF  Manufacturer  Siemens 
3  ABC123  DI  22  3  MODEL  Model  TRIO 
4  ABC123  DI  44  1  DEVTYPE  Device Type  PET 
5  ABC123  DI  44  2  MANUF  Manufacturer  Siemens 
6  ABC123  DI  44  3  MODEL  Model  INVEON 
 
Changeable properties and parameters of the devices identified in DI are represented in the DU domain. DUREFID is used to identify each unique scan, as 
defined by a changeable set of properties that were set as indicated for this scan.  
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Rows 1-13:   Show properties of the PET/CT device that were used in a scan of subject AD01-101. 
Rows 14-26:  Show properties of the PET/CT device that were used in a scan of subject AD01-102.  
Rows 27-39:  Show properties of the PET device that were used in a scan of subject AD01-103.  
 
du.xpt 
Row STUDYID DOMAIN USUBJID SPDEVID DUSEQ DUREFID  DUTESTCD  DUTEST  DUORRES DUORRESU … VISITNUM  DUDTC 
1  ABC123  DU  AD01-101  22  1  1236  ANTPLANE  Anatomical Plane  SAGITTAL    …  1  2012-05-22T09:30:00 
2  ABC123  DU  AD01-101  22  2  1236  INTSPACE  Interslice Spacing  1  mm  …  1  2012-05-22T09:30:00 
3  ABC123  DU  AD01-101  22  3  1236  SFTWRVER  Software Version  5.1    …  1  2012-05-22T09:30:00 
4  ABC123  DU  AD01-101  22  4  1236  STHICK  Slice Thickness  5  mm  …  1  2012-05-22T09:30:00 
5  ABC123  DU  AD01-101  22  5  1236  PIXSPCX  Pixel Spacing X  2  mm  …  1  2012-05-22T09:30:00 
6  ABC123  DU  AD01-101  22  6  1236  PIXSPCY  Pixel Spacing Y  2  mm  …  1  2012-05-22T09:30:00 
7  ABC123  DU  AD01-101  22  7  1236  AQMTRXSZ  Image Acquisition Matrix Size  256X256    …  1  2012-05-22T09:30:00 
8  ABC123  DU  AD01-101  22  8  1236  FLDVIEW  Field of View  280X280  mm  …  1  2012-05-22T09:30:00 
9  ABC123  DU  AD01-101  22  9  1236  NUMSLICE  Number of Slices  125    …  1  2012-05-22T09:30:00 
10  ABC123  DU  AD01-101  22  10  1236  ATTCRCT  Attenuation Correction Type  FBP    …  1  2012-05-22T09:30:00 
11  ABC123  DU  AD01-101  22  11  1236  DECCORR  Decay Correction  N    …  1  2012-05-22T09:30:00 
12  ABC123  DU  AD01-101  22  12  1236  RANDCORR  Randoms Correction  N    …  1  2012-05-22T09:30:00 
13  ABC123  DU  AD01-101  22  13  1236  RECONDAT  Reconstruction of Raw Data Type  Iterative    …  1  2012-05-22T09:30:00 
14  ABC123  DU  AD01-102  22  1  1237  ANTPLANE  Anatomical Plane  SAGITTAL    …  1  2012-05-22T08:00:00 
15  ABC123  DU  AD01-102  22  2  1237  INTSPACE  Interslice Spacing  1  mm  …  1  2012-05-22T08:00:00 
16  ABC123  DU  AD01-102  22  3  1237  SFTWRVER  Software Version  5.1    …  1  2012-05-22T08:00:00 
17  ABC123  DU  AD01-102  22  4  1237  STHICK  Slice Thickness  5  mm  …  1  2012-05-22T08:00:00 
18  ABC123  DU  AD01-102  22  5  1237  PIXSPCX  Pixel Spacing X  2  mm  …  1  2012-05-22T08:00:00 
19  ABC123  DU  AD01-102  22  6  1237  PIXSPCY  Pixel Spacing Y  2  mm  …  1  2012-05-22T08:00:00 
20  ABC123  DU  AD01-102  22  7  1237  AQMTRXSZ  Image Acquisition Matrix Size  256X256    …  1  2012-05-22T08:00:00 
21  ABC123  DU  AD01-102  22  8  1237  FLDVIEW  Field of View  280X280  mm  …  1  2012-05-22T08:00:00 
22  ABC123  DU  AD01-102  22  9  1237  NUMSLICE  Number of Slices  125    …  1  2012-05-22T08:00:00 
23  ABC123  DU  AD01-102  22  10  1237  ATTCRCT  Attenuation Correction Type  FBP    …  1  2012-05-22T08:00:00 
24  ABC123  DU  AD01-102  22  11  1237  DECCORR  Decay Correction  N    …  1  2012-05-22T08:00:00 
25  ABC123  DU  AD01-102  22  12  1237  RANDCORR  Randoms Correction  N    …  1  2012-05-22T08:00:00 
26  ABC123  DU  AD01-102  22  13  1237  RECONDAT  Reconstruction of Raw Data Type  Backscatter    …  1  2012-05-22T08:00:00 
27  ABC123  DU  AD01-103  44  1  1238  ANTPLANE  Anatomical Plane  SAGITTAL    …  1  2012-05-22T09:30:00 
28  ABC123  DU  AD01-103  44  2  1238  INTSPACE  Interslice Spacing  1  mm  …  1  2012-05-22T09:30:00 
29  ABC123  DU  AD01-103  44  3  1238  SFTWRVER  Software Version  5.1    …  1  2012-05-22T09:30:00 
30  ABC123  DU  AD01-103  44  4  1238  STHICK  Slice Thickness  5  mm  …  1  2012-05-22T09:30:00 
31  ABC123  DU  AD01-103  44  5  1238  PIXSPCX  Pixel Spacing X  2  mm  …  1  2012-05-22T09:30:00 
32  ABC123  DU  AD01-103  44  6  1238  PIXSPCY  Pixel Spacing Y  2  mm  …  1  2012-05-22T09:30:00 
33  ABC123  DU  AD01-103  44  7  1238  AQMTRXSZ  Image Acquisition Matrix Size  256X256    …  1  2012-05-22T09:30:00 
34  ABC123  DU  AD01-103  44  8  1238  FLDVIEW  Field of View  280X280  mm  …  1  2012-05-22T09:30:00 
35  ABC123  DU  AD01-103  44  9  1238  NUMSLICE  Number of Slices  125    …  1  2012-05-22T09:30:00 
36  ABC123  DU  AD01-103  44  10  1238  ATTCRCT  Attenuation Correction Type  FBP    …  1  2012-05-22T09:30:00 
37  ABC123  DU  AD01-103  44  11  1238  DECCORR  Decay Correction  N    …  1  2012-05-22T09:30:00 
38  ABC123  DU  AD01-103  44  12  1238  RANDCORR  Randoms Correction  N    …  1  2012-05-22T09:30:00 
39  ABC123  DU  AD01-103  44  13  1238  RECONDAT  Reconstruction of Raw Data Type  Backscatter    …  1  2012-05-22T09:30:00 
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Fixed properties of devices identified in DI are represented in the DO domain.  
 
Row 1:   Shows properties of the PET/CT scanner used.  
Row 2:   Shows properties of the PET scanner used.  
Row 3:   Shows the composition of the tube used to collect the CSF sample from the lumbar puncture in the PR domain. 
 
do.xpt 
Row  STUDYID  DOMAIN  SPDEVID  DOSEQ  DOTESTCD  DOTEST  DOORRES  DOORRESU 
1  ABC123  DO  22  1  DETCRYS  Detector Scintillation Crystals  Bismuth Germanium Oxide   
2  ABC123  DO  44  1  DETCRYS  Detector Scintillation Crystals  Bismuth Germanium Oxide   
3  ABC123  DO  8842  1  TUBECOMP  Tube Composition  Polypropylene   
 
The RELREC table below uses --LNKID to relate the PR and AG domains to each other and to NV and --REFID to relate NV and DU.  
 
In this example, the sponsor has maintained two sets of reference identifiers for the specific purpose of being able to relate records across multiple domains. 
Because the SDTMIG-MD advocates the use of --REFID to link a group of settings to the results obtained from the reading or interpretation of the test (see 
SDTMIG-MD v1.0, Section 4.2.1, Assumption 8), --LNKID has been used to establish the relationships between the procedure, the substance administered 
during the procedure, and the results obtained from the procedure. --LNKID is unique for each procedure for each subject, so datasets may be related to each 
other as a whole.  
  
Rows 1-2:  Show the relationship between the scan, represented in PR, and the radiolabel tracer used, represented in AG. There is only one tracer 
administration for each scan, and only one scan for each tracer administration, so the relationship is ONE to ONE.  
Rows 3-4:   Show the relationship between the scan, represented in PR, and the SUVR results obtained from the scan, represented in NV. Each scan yields two 
results, so the relationship is ONE to MANY.  
Rows 5-6:  Show the relationship between the radiolabel tracer used and the SUVR results for each scan. This relationship may seem indirect, but it is not: the 
choice of radiolabel has the potential to affect the results obtained. Because the relationship between PR and AG is ONE to ONE and the 
relationship between PR and NV is ONE to MANY, the relationship between AG and NV must be ONE to MANY.  
Rows 7-8:  Show the relationship between the SUVR results and the specific settings for the device used for each scan. There is more than one result from 
each scan, and more than one setting for each scan, so the relationship is MANY to MANY. This relationship is unusual and challenging to manage 
in a join/merge and only represents the concept of this relationship. To uniquely identify all the settings (DUTEST) related to an individual result 
(NVTEST), select an individual NVTEST and use its NVREFID to join/merge with the DUREFID to revise this to a ONE to MANY relationship 
to obtain all related DUTEST records. 
 
relrec.xpt 
Row  STUDYID  RDOMAIN  USUBJID  IDVAR  IDVARVAL  RELTYPE  RELID 
1  ABC123  PR    PRLNKID    ONE  6 
2  ABC123  AG    AGLNKID    ONE  6 
3  ABC123  PR     PRLNKID     ONE  7 
4  ABC123  NV     NVLNKID     MANY  7 
5  ABC123  AG     AGLNKID     ONE  8 
6  ABC123  NV     NVLNKID     MANY  8 
7  ABC123  NV    NVREFID    MANY  9 
8  ABC123  DU    DUREFID    MANY  9 
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3.3 Scales of Cognitive Function 
Many of the primary and secondary endpoints collected in trials of dementia conditions, such as AD and MCI, come in the form of clinical scales of 
cognition/function. These scales are typically represented in the Questionnaires (QS) Domain. The majority of the new documentation produced for this version 
of the Alzheimer’s User Guide originates from Questionnaire supplements, maintained as standalone guides on the CDISC website at 
http://www.cdisc.org/content2909 . 
 
The table below lists the scales that have been implemented in these supplemental user guides for AD as of the publication of this guide. Sponsors should refer to 
the link above if a scale of interest is not included below, as it may have been developed for another therapeutic area, and new scales are implemented in an 
ongoing basis by the QS Terminology and Standards Development subteams. See CDISC COP 017 CDISC SDTMIG Questionnaire Supplements 
(http://www.cdisc.org/bylaws-and-policies) for details on implementing or requesting development of standard questionnaires for SDTM-based submissions. 
 
Full Name and Abbreviation  Status of Permission to develop 
controlled terminology 
Status of controlled 
terminology 
Status of supplement 
development 
Clinical Dementia Rating Scale (CDR)†  Permission received  Terminology developed.  Supplement developed. 
Geriatric Depression Scale –(GDS)  Permission received  Terminology developed.  Supplement developed. 
Geriatric Depression Scale Short Form –(GDS-Short Version)  Permission received  Terminology developed.  Supplement developed. 
Functional Activities Questionnaire-(FAQ)  Permission received  Terminology developed.  Supplement developed. 
Functional Activities Questionnaire: NACC Version-(FAQ-
NACC)  Permission received  Terminology developed.  Supplement developed. 
Disability Assessment for Dementia-(DAD)  Permission received  Terminology developed.  Supplement developed. 
Activities of Daily Living Inventory - MCI (ADCS-ADL MCI)  Permission received  Terminology developed.  Supplement developed. 
Neuropsychiatric Inventory (NPI)  Permission received  Terminology developed.  Supplement developed. 
Alzheimer’s Disease Assessment Scale – Cognitive (ADAS-
Cog)  Permission received  Terminology developed.  Supplement developed. 
Mini-Mental State Examination (MMSE)  Permission denied  *  * 
Clinical Global Impression Questionnaire (CGI)  Permission received  Terminology developed.  Supplement developed. 
Modified Hachinski Ischemic Scale  Permission received  Terminology in 
development.  Supplement in development 
Auditory Verbal Learning Test (AVLT)  Permission Received  Terminology Developed  Supplement in development 
†Supplement is available on the CDISC website under the “Members Only” section. 
*In general, CDISC does not develop supplements for questionnaires for which permission to develop controlled terminology has been denied. A supplement for MMSE has been 
developed, but the terminology it uses is generic.  
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Appendices 
Appendix A: Work Group 
Core Development Team 
Name  Institution/Organization 
Jon Neville  Critical Path Institute 
Bob Stafford  Critical Path Institute 
Bess LeRoy  Critical Path Institute 
Steve Kopko  CDISC 
 
Clinical Science and Technical Subject Matter Experts 
Name  Institution/Organization 
Andreas Jeromin  NextGen Sciences  
Jerry Novak  Johnson & Johnson 
Pat Cole  Lilly 
Mark Austin  Ixico 
Karen Crawford  LONI/ADNI 
Joyce Suhy  Synarc 
Susan De Santi  GE 
Diane Stephenson  Critical Path Institute/CAMD 
 
Terminology and Questionnaires Supplement Development 
Name  Institution/Organization 
Bernice Yost  CDISC 
Erin Muhlbradt  NCI EVS 
Roberta Rosenberg  Pfizer 
Gary Cunningham   Teva 
Jordan Li  NCI EVS 
Donna Sattler  MaxisIT 
Fred Wood  Accenture 
Randall Austin  Glaxo-Smith Kline 
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Appendix B: Glossary and Abbreviations 
 
Appendix B1: Supplemental Qualifiers Name Codes 
The following table contains additional standard QNAM and QLABEL values for use in the Supplemental 
Qualifiers (SUPP--) special-purpose datasets.  
 
QNAM  QLABEL  Applicable Domains 
MHOSTDTC  Onset of Symptoms Date  MH 
SFTWR  Analysis Software  MO 
SFTWRVER  Software Version  MO 
REFREG  Reference Region  NV 
 
Appendix C: Additional Assumptions for Domains 
The domains used in this document operate under certain assumptions, which may be found with the domain 
specification tables in the implementation guides to which they belong (e.g., the SDTMIG for domains pertaining to 
human clinical trials, the SDTMIG-MD for domains pertaining to the use of medical devices, the SDTM APIG for 
domains pertaining to persons who are relevant to the study without being study subjects). All of the assumptions 
from those implementation guides apply for this user guide. The assumptions given below apply to TAUG-
Alzheimer’s in addition to the standard assumptions.  
Appendix C1: General Assumptions for AD/MCI 
1.  Controlled terminology is still under development for the AD data standards, thus some values in the 
examples are not CDISC controlled terms. Sponsors should always check terminology shown in the 
examples against current controlled terminology before adopting it. 
AD  Alzheimer’s Disease 
CAMD  Coalition Against Major Diseases, a program of the Critical Path Institute 
CDE  Common Data Element 
CDISC  Clinical Data Interchange Standards Consortium 
C-Path  Critical Path Institute  
CRF  Case Report Form 
CSF  Cerebrospinal Fluid  
DICOM  Digital Imaging and Communications in Medicine 
FDA  Food and Drug Administration 
FDG  18Fluorodeoxy Glucose- a radiolabeled tracer used in Positron Emission Tomography 
MCI  Mild Cognitive Impairment 
MRI  Magnetic Resonance Imaging 
NCI EVS  National Cancer Institute Enterprise Vocabulary Services 
PET  Positron Emission Tomography 
PET/CT  Positron Emission Tomography-Computerized Tomography, a combination scanner using PET and CT 
SDS  Submission Data Standards 
SDTM  Study Data Tabulation Model 
SDTMIG  Study Data Tabulation Model Implementation Guide for Human Clinical Trials 
SDTMIG-MD  Study Data Tabulation Model Implementation Guide for Medical Devices 
SME  Subject Matter Expert 
SRC  Standards Review Council 
SUVR  Standard Uptake Value Ratio 
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Appendix C2: Additional Assumptions for Procedure Agents Domain 
Model 
1.  AGLNKID ties the radiopharmaceutical to the imaging procedure in the PR domain. 
2.   It is important to know the time elapsed between tracer injection and the start of the scan. 
Therefore, it is important to record AGSTDTC to the level of minutes, or even seconds. Time 
elapsed can then be determined by the difference in AGSTDTC and PRSTDTC (scan start time). 
Appendix C3: Additional Assumptions for Procedures Domain Model 
1.  Sponsors should use the PR domain to represented procedures such as lumbar puncture and imaging, 
including MRI or PET scans, if such data was collected. Subsequent handling of the CSF specimen 
obtained via lumbar puncture (aliquoting, freezing, thawing) should be represented in the Biospecimen 
domains (BE and BS), if collected. Any results related to CSF samples or imaging should be represented in 
the appropriate findings domains (LB, NV, or MO), as shown in the domain examples. 
2.  PRLNKID is used to connect the imaging procedure with scan results. In the case of PET imaging, it is also 
used to link to the radiolabeled tracer information. 
3.  PRREFID is equal to BEREFID when BECAT=COLLECTION.  
Appendix C4: Additional Assumptions for Medical History Domain 
Model 
1.   “Alzheimer’s disease”, “mild cognitive impairment”, or other terms relating to Alzheimer’s-type 
dementias for which the study is being conducted should be represented in MHTERM when 
MHCAT=Primary Diagnosis. Coding to the Preferred Term with MedDRA for Alzheimer’s disease or mild 
cognitive impairment to populate MHDECOD is optional but encouraged. See Section 2.2 for how to map 
the primary diagnosis. 
2.  MHSTDTC should be populated with the date of diagnosis when MHCAT=PRIMARY DIAGNOSIS. 
3.  If general medical history information is also captured either as verbatim text or pre-specified text, it can be 
coded with MedDRA and the Preferred Term reported in MHDECOD based on the sponsor’s coding 
criteria for medical history. 
4.  Terminology: 
a.  The terminology for MHCAT includes “PRIMARY DIAGNOSIS and “GENERAL.” 
b.  Note that MHCAT is not subject to controlled terminology, and this is just a recommendation. 
c.  Where collected, onset date of symptoms for either Alzheimer’s disease or MCI should be mapped 
to Supplemental Qualifiers (SUPPMH).  
d.  Existing CDISC Controlled Terminology should be used for the MH domain. There is no 
additional CDISC Controlled Terminology needed for the MH domain for AD. 
Appendix C5: Additional Assumptions for Laboratory Test Results 
Domain Model 
1.  If lab results were obtained from an aliquot derived from the original sample, the unique identifier for 
the aliquot (value in BSREFID/BEREFID), if important, should be represented in LBREFID as well.  
2.  If a device (such as a 96-well plate) is directly used to obtain a lab result, SPDEVID should be 
populated to match the SPDEVID of the corresponding device in the DI domain.  
Appendix C6: Additional Assumptions for Morphology Domain Model 
1.  SPDEVID identifies the MRI scanner used to acquire these measures. It should be matched with the 
same SPDEVID in the device domains.  
2.  MOREFID links the morphology result to the particular scan and the properties/settings of the scan in 
the Device In-Use domain (DUREFID). 
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3.  MOLNKID links the morphology result to the image acquisition procedure in the PR domain 
(PRLNKID). 
4.  When the method used to determine the results shown is SOFTWARE ANALYSIS (as in the example 
in Section 3.2.1.2), the software used to analyze the images should be represented in SUPPMO. The 
software name and version should be linked to the subject identifier.  
Appendix C7: Additional Assumptions for Nervous System Findings 
Domain Model 
1.  Sponsors should represent as many target brain regions for which they calculated SUVR values, using 
one SUVR test per row and showing each associated brain region in NVLOC. Associated qualifiers of 
NVLOC (NVLAT, NVDIR) may be used where appropriate. The examples shown in Section 3.2.2.2 
are not meant to be all inclusive. Each reference region used for SUVR determination should be listed 
in the SUPPNV domain, linking back to the SUVR record to which it applies. 
2.  NVREFID relates SUVR values obtained from an imaging scan to the scan properties/settings in the 
DU domain (DUREFID).  
3.  NVLNKID links the result in NV to the radiolabeled tracer used in the AG domain to (AGLNKID). It 
is important to maintain this link as it defines the tracer used, and therefore the target biomarker being 
imaged. It also links the result to the imaging procedure in the PR domain (PRLNKID).  
4.  SPDEVID shows the scanner ID number used to generate the images from which these results were 
obtained.  
Appendix C8: Additional Assumptions for Pharmacogenomic/Genetics 
Domains 
1.  BE domain:  
a.  Information about Biospecimen Events (such as collection, aliquoting, freezing) is represented in 
detail in the BE domain. Since each sample needs a separate identifier to link it to further actions 
or characteristics of the sample, each aliquoting event is assigned a unique BEREFID value that 
can be traced to the BEREFID assigned for the collected “parent” sample. BEREFID is used to 
connect the BE and BS (BSREFID) domains, as well as to any results in the LB domain 
(LBREFID) obtained from the sample.  
2.  BS domain:  
a.  SPDEVID identifies the device associated with any biospecimen property. It links the BS domain 
with the device domains. 
b.  BSREFID links the listed findings of the biospecimen to any biospecimen events by linking to 
BEREFID.  
3.  PF domain:  
a.  If genotyping information is collected it should be represented in the Pharmacogenomics Findings 
domain. 
Appendix C9: Additional Assumptions for Medical Device Domains 
1.  DI domain: The information for tube type in this domain refers to a specific lot of tubes, since the 
properties within a lot do not change. Properties of tubes were identified as being important to interpreting 
results of biomarker tests. In cases where the tube properties or the properties of any other “devices” are not 
deemed important to interpreting results, they do not need to be represented.  
Appendix C10: Additional Assumptions for Associated Persons 
Domains 
1.  AD special-interest terminology for the following Associated Persons domains is displayed in the 
examples. Note that controlled terminology is currently out-of-scope for MHCAT and MHTERM. All other 
controlled terminology should be used as appropriate. 
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a.  Medical History: MHCAT and MHTERM use AD special-interest terminology 
i.  MHCAT=PRIMARY DIAGNOSIS 
ii.  MHTERM= Alzheimer's disease or Mild Cognitive Impairment 
Appendix D: Representations and Warranties, Limitations of 
Liability, and Disclaimers 
CDISC Patent Disclaimers 
It is possible that implementation of and compliance with this standard may require use of subject matter covered by 
patent rights. By publication of this standard, no position is taken with respect to the existence or validity of any 
claim or of any patent rights in connection therewith. CDISC, including the CDISC Board of Directors, shall not be 
responsible for identifying patent claims for which a license may be required in order to implement this standard or 
for conducting inquiries into the legal validity or scope of those patents or patent claims that are brought to its 
attention. 
 
Representations and Warranties 
“CDISC grants open public use of this User Guide (or Final Standards) under CDISC’s copyright.”  
 
Each Participant in the development of this standard shall be deemed to represent, warrant, and covenant, at the time 
of a Contribution by such Participant (or by its Representative), that to the best of its knowledge and ability: (a) it 
holds or has the right to grant all relevant licenses to any of its Contributions in all jurisdictions or territories in 
which it holds relevant intellectual property rights; (b) there are no limits to the Participant’s ability to make the 
grants, acknowledgments, and agreements herein; and (c) the Contribution does not subject any Contribution, Draft 
Standard, Final Standard, or implementations thereof, in whole or in part, to licensing obligations with additional 
restrictions or requirements inconsistent with those set forth in this Policy, or that would require any such 
Contribution, Final Standard, or implementation, in whole or in part, to be either: (i) disclosed or distributed in 
source code form; (ii) licensed for the purpose of making derivative works (other than as set forth in Section 4.2 of 
the CDISC Intellectual Property Policy (“the Policy”)); or (iii) distributed at no charge, except as set forth in 
Sections 3, 5.1, and 4.2 of the Policy. If a Participant has knowledge that a Contribution made by any Participant or 
any other party may subject any Contribution, Draft Standard, Final Standard, or implementation, in whole or in 
part, to one or more of the licensing obligations listed in Section 9.3, such Participant shall give prompt notice of the 
same to the CDISC President who shall promptly notify all Participants. 
 
No Other Warranties/Disclaimers. ALL PARTICIPANTS ACKNOWLEDGE THAT, EXCEPT AS PROVIDED 
UNDER SECTION 9.3 OF THE CDISC INTELLECTUAL PROPERTY POLICY, ALL DRAFT STANDARDS 
AND FINAL STANDARDS, AND ALL CONTRIBUTIONS TO FINAL STANDARDS AND DRAFT 
STANDARDS, ARE PROVIDED “AS IS” WITH NO WARRANTIES WHATSOEVER, WHETHER EXPRESS, 
IMPLIED, STATUTORY, OR OTHERWISE, AND THE PARTICIPANTS, REPRESENTATIVES, THE CDISC 
PRESIDENT, THE CDISC BOARD OF DIRECTORS, AND CDISC EXPRESSLY DISCLAIM ANY 
WARRANTY OF MERCHANTABILITY, NONINFRINGEMENT, FITNESS FOR ANY PARTICULAR OR 
INTENDED PURPOSE, OR ANY OTHER WARRANTY OTHERWISE ARISING OUT OF ANY PROPOSAL, 
FINAL STANDARDS OR DRAFT STANDARDS, OR CONTRIBUTION. 
 
Limitation of Liability 
IN NO EVENT WILL CDISC OR ANY OF ITS CONSTITUENT PARTS (INCLUDING, BUT NOT LIMITED 
TO, THE CDISC BOARD OF DIRECTORS, THE CDISC PRESIDENT, CDISC STAFF, AND CDISC 
MEMBERS) BE LIABLE TO ANY OTHER PERSON OR ENTITY FOR ANY LOSS OF PROFITS, LOSS OF 
USE, DIRECT, INDIRECT, INCIDENTAL, CONSEQUENTIAL, OR SPECIAL DAMAGES, WHETHER 
UNDER CONTRACT, TORT, WARRANTY, OR OTHERWISE, ARISING IN ANY WAY OUT OF THIS 
POLICY OR ANY RELATED AGREEMENT, WHETHER OR NOT SUCH PARTY HAD ADVANCE NOTICE 
OF THE POSSIBILITY OF SUCH DAMAGES. 
 
Note: The CDISC Intellectual Property Policy can be found at  
http://www.cdisc.org/about/bylaws_pdfs/CDISCIPPolicy-FINAL.pdf. 
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6 Domain Models Based on the General 
Observation Classes 
6.1 Interventions 
AG – Procedure Agents 
Some tests involve administration of substances, and it has been unclear what domain these should be stored in.  The Concomitant Medications domain seemed 
particularly inappropriate when the substance was one that would never been given as a medication.  Even substances that are medications are not being used as 
such when they are given as part of a testing procedure.  The Exposure domain also seemed inappropriate, since although the testing procedure might be part of 
the study plan, these data would not be used or analyzed in the same way as data about study treatments.  The Procedure Agents domain was created to fill this 
gap.  The Procedure Agents domain has advantages over the draft Procedures domain for this purpose. It allows recording of multiple substance administrations 
for a single testing procedure.  It also separates data about substance administrations from data about procedures which do not involve substance administration. 
AG – Description/Overview for Procedure Agents Domain Model 
The Procedure Agents domain is a draft domain at the time of this publication. No CDISC controlled terminology definition exists for the domain yet. 
 
Both the provisional Procedures domain and this draft Procedure Agents domain allow collection of doses administered during a procedure, and discussions are 
ongoing to provide guidance on deciding what data should be stored in which domain. The draft Procedure Agents domain can be used to provide data on several 
substance administrations within the same procedure, as shown in Example 2 below. 
AG – Specification for Procedure Agents Domain Model 
ag.xpt, Procedure Agents — Interventions, Version 3.x.x. One record per recorded intervention occurrence per subject, Tabulation.  
Variable Name  Variable Label  Type 
Controlled 
Terms, Codelist 
or Format 
Role  CDISC Notes  Core 
STUDYID  Study Identifier  Char    Identifier  Unique identifier for a study.  Req 
DOMAIN  Domain Abbreviation  Char  AG  Identifier  Two-character abbreviation for the domain.  Req 
USUBJID  Unique Subject Identifier  Char    Identifier  Identifier used to uniquely identify a subject across all studies for all 
applications or submissions involving the product. 
Req 
AGSEQ  Sequence Number  Num    Identifier  Sequence Number given to ensure uniqueness of subject records within a 
domain. May be any valid number. 
Req 
AGGRPID  Group ID  Char    Identifier  Used to tie together a block of related records in a single domain for a subject.  Perm 
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AGSPID  Sponsor-Defined Identifier  Char    Identifier  Sponsor-defined reference number. Perhaps pre-printed on the CRF as an 
explicit line identifier or defined in the sponsor's operational database. 
Example: Line number from the procedure or test page. 
Perm 
AGTRT  Reported Agent Name  Char    Topic  Verbatim medication name that is either pre-printed or collected on a CRF.  Req 
AGMODIFY  Modified Reported Name  Char    Synonym 
Qualifier 
If AGTRT is modified to facilitate coding, then AGMODIFY will contain the 
modified text. 
Perm 
AGDECOD  Standardized Agent Name  Char  *  Synonym 
Qualifier 
Standardized or dictionary-derived text description of AGTRT or 
AGMODIFY. Equivalent to the generic medication name in WHO Drug. The 
sponsor is expected to provide the dictionary name and version used to map 
the terms utilizing the define.xml external codelist attributes. If an intervention 
term does not have a decode value in the dictionary then AGDECOD will be 
left blank. 
Perm 
AGCAT  Category for Agent  Char  *  Grouping 
Qualifier 
Used to define a category of agent. Examples: CHALLENGE AGENT, or 
PET TRACER. 
Perm 
AGSCAT  Subcategory for Agent  Char  *  Grouping 
Qualifier 
Further categorization of agent.  Perm 
AGPRESP  AG Pre-Specified  Char  (NY)  Record 
Qualifier 
Used to indicate whether (Y/null) information about the use of a specific agent 
was solicited on the CRF. 
Perm 
AGOCCUR  AG Occurrence  Char  (NY)  Record 
Qualifier 
When the use of specific agent is solicited, AGOCCUR is used to indicate 
whether or not (Y/N) use of the agent occurred. Values are null for agents not 
specifically solicited. 
Perm 
AGSTAT  Completion Status  Char  (ND)  Record 
Qualifier 
Used to indicate that a question about a pre-specified agent was not answered. 
Should be null or have a value of NOT DONE. 
Perm 
AGREASND  Reason Test Not Performed  Char    Record 
Qualifier 
Describes the reason procedure agent was not collected. Used in conjunction 
with AGSTAT when value is NOT DONE. 
Perm 
AGCLAS  Agent Class  Char  *  Variable 
Qualifier 
Drug class. May be obtained from coding. When coding to a single class, 
populate with class value. If using a dictionary and coding to multiple classes, 
then follow assumption 4.1.2.8.3 or omit AGCLAS. 
Perm 
AGCLASCD  Agent Class Code  Char  *  Variable 
Qualifier 
Class code corresponding to AGCLAS. Drug class. May be obtained from 
coding. When coding to a single class, populate with class code. If using a 
dictionary and coding to multiple classes, then follow assumption 4.1.2.8.3 or 
omit AGCLASCD. 
Perm 
AGDOSE  Dose per Administration  Num    Record 
Qualifier 
Amount of AGTRT taken.  Perm 
AGDOSTXT  Dose Description  Char    Record 
Qualifier 
Dosing amounts or a range of dosing information collected in text form. Units 
may be stored in AGDOSU. Example: 200-400, 15-20. 
Perm 
AGDOSU  Dose Units  Char  (UNIT)  Variable 
Qualifier 
Units for AGDOSE and AGDOSTXT. Examples: ng, mg, or mg/kg.  Perm 
AGDOSFRM  Dose Form  Char  (FRM)  Variable 
Qualifier 
Dose form for AGTRT. Examples: TABLET, AREOSOL.  Perm 
AGDOSFRQ  Doing Frequency per 
Interval 
Char  (FREQ)  Variable 
Qualifier 
Usually expressed as the number of repeated administrations of AGDOSE 
within a specific time period. Example: ONCE 
Perm 
AGROUTE  Route of Administration  Char  (ROUTE)  Variable 
Qualifier 
Route of administration for AGTRT. Examples: ORAL.  Perm 
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VISITNUM  Visit Number  Num    Timing  1. Clinical encounter number.  
2. Numeric version of VISIT, used for sorting. 
Exp 
VISIT  Visit Name  Char    Timing  1. Protocol-defined description of clinical encounter.  
2. May be used in addition to VISITNUM and/or VISITDY. 
Perm 
VISITDY  Planned Study Day of Visit  Num    Timing  Planned study day of the visit based upon RFSTDTC in Demographics.  Perm 
AGSTDTC  Start Date/Time of Agent  Char  ISO 8601  Timing    Perm 
AGENDTC  End Date/Time of Agent  Char  ISO 8601  Timing    Perm 
AGSTDY  Study Day of Start of Agent  Num    Timing  Study day of start of agent relative to the sponsor-defined RFSTDTC.  Perm 
AGENDY  Study Day of End of Agent  Num    Timing  Study day of end of agent relative to the sponsor-defined RFSTDTC.  Perm 
AGDUR  Duration of Agent  Char  ISO 8601  Timing  Collected duration for an agent episode. Used only if collected on the CRF and 
not derived from start and end date/times. 
Perm 
AGSTRF  Start Relative to Reference 
Period 
Char  (STENRF)  Timing  Describes the start of the agent relative to sponsor-defined reference period. 
The sponsor-defined reference period is a continuous period of time defined 
by a discrete starting point and a discrete ending point (represented by 
RFSTDTC and RFENDTC in Demographics). If information such as 
"PRIOR", "ONGOING", or "CONTINUING" was collected, this information 
may be translated into AGSTRF. 
Perm 
AGENRF  End Relative to Reference 
Period 
Char  (STENRF)  Timing  Describes the end of the agent relative to the sponsor-defined reference period. 
The sponsor-defined reference period is a continuous period of time defined 
by a discrete starting point and a discrete ending point (represented by 
RFSTDTC and RFENDTC in Demographics). If information such as 
"PRIOR", "ONGOING", or "CONTINUING" was collected, this information 
may be translated into AGENRF. 
Perm 
AGSTRTPT  Start Relative to Reference 
Time Point 
Char  BEFORE, 
COINCIDENT, 
AFTER, U 
Timing  Identifies the start of the agent as being before or after the reference time point 
defined by variable AGSTTPT. 
Perm 
AGSTTPT  Start Reference Time Point  Char    Timing  Description or date/time in ISO 8601 character format of the reference point 
referred to by AGSTRTPT. Examples: "2003-12-15" or "VISIT 1". 
Perm 
AGENRTPT  End Relative to Reference 
Time Point 
Char  BEFORE, 
COINCIDENT, 
AFTER, 
ONGOING, U 
Timing  Identifies the end of the agent as being before or after the reference time point 
defined by variable AGENTPT. 
Perm 
AGENTPT  End Reference Time Point  Char    Timing  Description or date/time in ISO 8601 character format of the reference point 
referred to by AGENRTPT. Examples: "2003-12-25" or "VISIT 2". 
Perm 
* Indicates variable may be subject to controlled terminology, (Parenthesis indicates CDISC/NCI codelist code value) 
AG – Assumptions for Procedure Agents Domain Model 
1.  AG Definition and Structure  
a.  CRF data that captures the agents administered to the subject as part of a procedure or assessment as opposed to drugs, medications and 
therapies administered with therapeutic intent. An example is a short-acting bronchodilator administered as part of a reversibility assessment. 
Other examples of substance administrations that could be submitted in this domain include contrast agents and radio labeled substances used 
in imaging studies. Discussions are ongoing on the handling of radiation (e.g., x-rays or visible light) in SDTM interventions domains. 
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b.  The structure of the AG domain is one record per agent intervention episode, or pre-specified agent assessment per subject. It is the sponsor's 
responsibility to define an intervention episode. This definition may vary based on the sponsor's requirements for review and analysis.  
2.  Procedure Agent Description and Coding  
a.  AGTRT captures the name of the agent and it is the topic variable. It is a required variable and must have a value. AGTRT should include only 
the agent name, and should not include dosage, formulation, or other qualifying information. For example, ALBUTEROL 2 PUFF is not a 
valid value for AGTRT. This example should be expressed as AGTRT = ALBUTEROL, AGDOSE = 2, AGDOSU = PUFF, and AGDOSFRM 
= AEROSOL  
b.  AGMODIFY should be included if the sponsor‘s procedure permits modification of a verbatim term for coding.  
c.  AGDECOD is the standardized agent term derived by the sponsor from the coding dictionary. It is possible that the reported term (AGTRT) or 
the modified term (AGMODIFY) can be coded using a standard dictionary. In this instance the sponsor is expected to provide the dictionary 
name and version used to map the terms utilizing the define.xml external codelist attributes.  
3.  Pre-specified Terms; Presence or Absence of Procedure Agents 
a.  AGPRESP is used to indicate whether an agent was pre-specified. 
b.  AGOCCUR is used to indicate whether a pre-specified agent was used. A value of Y indicates that the agent was used and N indicates that it 
was not.  
c.  If an agent was not pre-specified the value of AGOCCUR should be null. AGPRESP and AGOCCUR are permissible fields and may be 
omitted from the dataset if all agents were collected as free text. Values of AGOCCUR may also be null for pre-specified agents if no Y/N 
response was collected; in this case, AGSTAT = NOT DONE, and AGREASND could be used to describe the reason the answer was missing.  
4.  Additional Permissible Interventions Qualifiers  
a.  The variables --INDC, --DOSTOT, and --DOSRGM from the Interventions general observation class would not generally be used in the AG 
domain because AG should only contain agents used as part of a procedure or an assessment. 
b.  Other additional Qualifiers from the SDTM Interventions Class may be added to this domain.  
AG – Examples for Procedure Agents Domain Model 
Example 1 
This example shows the administration of a procedure agent administered as part of a reversibility assessment with the associated spirometer results, as well as 
the spirometry measurements (RE domain) obtained before and after agent administration. Depending on the study design, the route of bronchodilator 
administration (via meter dose inhaler (MDI) or nebulizer) and dose per actuation (puff) or nebule may also be collected. 
 
Reversibility Assessment 
Date of assessment: DD-MMM-YYYY 
Was the subject administered a short-acting bronchodilator in the previous 4 hours?  Yes  No 
Pre-Bronchdilator Spirometry (5 Minutes before Albuterol Dosing) 
Time of Assessment: HH:MM 
Forced Expiratory Volume in 1 Second (FEV1) Result: ______L 
Albuterol Administration 
Was the subject administered Albuterol?  Yes  No 
Time of Assessment: HH:MM     
Number of Puffs administered: ____     
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Post-Bronchdilator Spirometry (20 Minutes after Albuterol Dosing) 
Time of Assessment: HH:MM 
Forced Expiratory Volume in 1 Second (FEV1) Result: ______L 
Percentage Reversibility: _____ % 
 
Row 1:  Shows the administration data of an agent (Albuterol) which was pre-specified on the CRF as part of the reversibility procedure. 
 
ag.xpt 
Row  STUDYID  DOMAIN  USUBJID  AGSEQ  AGTRT  AGPRESP  AGOCCUR  AGDOSE  AGDOSU  AGDOSFRM  AGDOSFRQ  AGROUTE  VISIT  AGSTDTC 
1  XYZ  AG  XYZ-001-
001  1  ALBUTEROL  Y  Y  2  PUFF  AEROSOL  ONCE  ORAL  VISIT 
2 
2013-06-
18T10:05 
 
Row 1:  Shows the record where the question as to whether a short-acting bronchodilator was administered in the 4 hours prior to the reversibility 
assessment. A short-acting bronchodilator administered prior to the reversibility test, is used with therapeutic intent so is tabulated in the CM 
domain. Note that AGTRT has been populated with a description of a kind of medication rather than a single medication.  
 
cm.xpt 
Row  STUDYID  DOMAIN  USUBJID  CMSEQ  CMTRT  CMPRESP  CMOCCUR  CMEVLINT 
1  XYZ  CM  XYZ-001-001  1  SHORT-ACTING BRONCHODILATOR  Y  N  -PT4H 
 
Row 1:  Shows the data in original and standardized units of measure in REORRES, RESTRESC and RESTRESN for FEV1 of a pre-bronchodilator-
administration spirometry test performed as part of a reversibility assessment with the associated timing reference variables RETPT, RETPTNUM, 
REELTM, RETPTREF, and RERFTDTC. This test was performed 5 minutes before the bronchodilator challenge. 
Row 2:  Shows the data in original and standardized units of measure in REORRES, RESTRESC and RESTRESN for FEV1 of a post-bronchodilator 
administration spirometry test performed as part of a reversibility assessment with the associated timing reference variables RETPT, RETPTNUM, 
REELTM, RETPTREF, and RERFTDTC. This test was performed 20 minutes after the bronchodilator challenge. 
Row 3:  Shows the data in original and standardized units of measure in REORRES, RESTRESC and RESTRESN for the percentage reversibility where 
this is collected. 
 
re.xpt 
Row  STUDYID  DOMAIN  USUBJID  SPDEVID  RESEQ  REGRPID  RETESTCD  RETEST  REORRES  REORRESU  RESTRESC  RESTRESN 
1  XYZ  RE  XYZ-001-001  ABC001  1  1  FEV1  Forced Expiratory Volume in 1 Second  2.43  L  2.43  2.43 
2  XYZ  RE  XYZ-001-001  ABC001  2  1  FEV1  Forced Expiratory Volume in 1 Second  2.77  L  2.77  2.77 
3  XYZ  RE  XYZ-001-001  ABC001  3  1  PCTREV  Percentage Reversibility  13.99  %  13.99  13.99 
 
Row  RESTRESU  VISIT  REDTC  RETPT  RETPTNUM  REELTM  RETPTREF  RERFTDTC 
1 (cont)  L  VISIT 2  2013-06-18T10:00  PRE-BRONCHODILATOR 
ADMINISTRATION  1  -PT5M  BRONCHODILATOR 
ADMINISTRATION  2013-06-18T10:05 
2 (cont)  L  VISIT 2  2013-06-18T10:25  POST-BRONCHODILATOR 
ADMINISTRATION  2  PT20M  BRONCHODILATOR 
ADMINISTRATION  2013-06-18T10:05 
3 (cont)  %  VISIT 2  2013-06-18T10:25        BRONCHODILATOR 
ADMINISTRATION  2013-06-18T10:05 
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Row 1:  Shows the device type that was used for the pulmonary function tests as part of the reversibility procedure. 
 
di.xpt 
Row  STUDYID  DOMAIN  SPDEVID  DISEQ  DIPARMCD  DIPARM  DIVAL 
1  XYZ  DI  ABC001  1  TYPE  Device Type  SPIROMETER 
 
Rows 1-3:  Shows the relationship of the test agent to the spirometry measurements obtained before and after its administration and to the prior occurrence of 
short acting bronchodilator administration. 
 
relrec.xpt 
Row  STUDYID  RDOMAIN  USUBJID  IDVAR  IDVARVAL  RELTYPE  RELID 
1  XYZ  AG  XYZ-001-001  AGSEQ  1    1 
2  XYZ  RE  XYZ-001-001  REGRPID  1    1 
3  XYZ  CM  XYZ-001-001  CMSEQ  1    1 
 
Example 2 
This example captures data about the allergen used by the subject as part of a bronchial allergen challenge (BAC) test. Initially, the subject had a skin prick 
allergen test to help identify the allergen to be used for the BAC test. The allergens tested were cat dander, house dust mite, and grass. For this subject, grass 
provided the largest skin test reaction and was the allergen chosen to be used in the BAC test. A predetermined set of ascending doses of the chosen allergen are 
used in the screening BAC test. The results of the screening BAC are used to choose the allergen dose that will be used in subsequent BAC tests (not shown). 
 
Allergen Used?   Inhalation 
End Time 
Allergen Concentration  Time of 
FEV1  FEV1 (L)  ☐ Cat Dander  SQ-u/mL 
☐ House Dust Mites  ___:___  Saline=0  0  ___:___  __.__ 
☐ Grass  ___:___  Dose1  250  ___:___  __.__ 
  ___:___  Dose2  1000  ___:___  __.__ 
  ___:___  Dose3  2000  ___:___  __.__ 
 
Rows 1-3:  Correspond to the first part of the CRF. The skin response results corresponding to these allergen administrations were used to choose grass as the 
allergen for the BAC. 
Rows 4:  The first dose given in the BAC was saline. 
Rows 5-6:  Three successively higher doses of grass allergen were given. 
 
ag.xpt 
Row STUDYID DOMAIN  USUBJID  AGSEQ  AGTRT  AGPRESP AGOCCUR AGDOSE AGDOSU  AGROUTE  VISIT  AGENDTC 
1  XYZ  AG  XYZ-001-001  1  CAT DANDER  Y  N      INTRAEPIDERMAL  SCREENING  2010-10-31 
2  XYZ  AG  XYZ-001-001  2  HOUSE MITE DUST  Y  N      INTRAEPIDERMAL  SCREENING  2010-10-31 
2  XYZ  AG  XYZ-001-001  3  GRASS  Y  Y      INTRAEPIDERMAL  SCREENING  2010-10-31 
3  XYZ  AG  XYZ-001-001  4  SALINE  Y  Y  0  SQ-u/mL  RESPIRATORY (INHALATION) SCREENING 2010-11-07T10:56:00 
4  XYZ  AG  XYZ-001-001  5  GRASS  Y  Y  250  SQ-u/mL  RESPIRATORY (INHALATION) SCREENING 2010-11-07T11:19:00 
5  XYZ  AG  XYZ-001-001  6  GRASS  Y  Y  1000  SQ-u/mL  RESPIRATORY (INHALATION) SCREENING 2010-11-07T11:43:00 
6  XYZ  AG  XYZ-001-001  7  GRASS  Y  Y  2000  SQ-u/mL  RESPIRATORY (INHALATION) SCREENING 2010-11-07T12:06:00 
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3 Biospecimen Domains 
3.1 Biospecimen Events (BE) 
3.1.1 Description/Overview for Biospecimen Events Domain Model 
 The BE domain has no controlled terminology definiton yet.  
 
--PARENT and --SPCLVL are variables for recording the hierarchy of specimen relationships. There is some question as to whether they belong in BE, BS, or as 
part of a special purpose relationships dataset (RELSPEC). For now, all three options are given.  
3.1.2 Specification for Biospecimen Events Domain Model 
be.xpt, Biospecimen Events — Events. One record per biospecimen event per specimen collected per subject, Tabulations 
Variable Name  Variable Label  Type 
Controlled 
Terms, Codelist 
or Format 
Role  CDISC Notes  Core 
STUDYID  Study Identifier  Char     Identifier  Unique identifier for a study.  Req 
DOMAIN  Domain Abbreviation  Char   BE  Identifier  Two-character abbreviation for the domain.  Req 
USUBJID  Unique Subject Identifier  Char     Identifier  Identifier used to uniquely identify a subject across all studies for all applications 
or submissions involving the product. 
Req 
SPDEVID  Sponsor Device Identifier  Char    Identifier  Sponsor-defined identifier for a device.   Perm 
BESEQ  Sequence Number  Num     Identifier  Sequence Number given to ensure uniqueness of subject records within a domain. 
May be any valid number.  
Req 
BEGRPID  Group ID  Char     Identifier  Used to tie together a block of related records in a single domain.  Perm 
BEREFID  Reference ID   Char    Identifier  Optional internal or external identifier such as lab specimen ID.  Perm 
BESPID  Sponsor-Defined Identifier  Char    Identifier  Optional sponsor-defined reference number. Perhaps pre-printed on the CRF as 
an explicit line identifier or defined in the sponsor’s operational database. 
Example: Line number on a CRF page. 
Perm 
BETERM  Reported Term for the 
Biospecimen Event 
Char     Topic  Topic variable for an event observation, which is the verbatim or pre-specified 
name of the event. 
Req 
BEMODIFY  Modified Reported Term  Char     Synonym 
Qualifier 
If BETERM is modified to facilitate coding, then BEMODIFY will contain the 
modified text.  
Perm 
BEDECOD  Dictionary-Derived Term  Char  *  Synonym 
Qualifier 
Dictionary-derived text description of BETERM or BEMODIFY. CDISC 
vocabulary will be defined.  
Exp 
BEPARTY  Accountable Party   Char  *  Record 
Qualifier  
Person or organization accountable for the specimen at the conclusion of the 
action specified in BETERM.  
Perm 
BEPRTYID  Identification of specific 
accountable party  
Char    Record 
Qualifier  
An identifier for the responsible group/role (e.g. site, subject).   Perm 
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Variable Name  Variable Label  Type 
Controlled 
Terms, Codelist 
or Format 
Role  CDISC Notes  Core 
BECAT  Category for Biospecimen 
Event 
Char  *  Grouping 
Qualifier 
Used to define a category of related records. Example: COLLECTION, PREP, 
TRANSPORT 
Perm 
BESCAT  Subcategory for 
Biospecimen Event 
Char  *  Grouping 
Qualifier 
A further categorization of biospecimen event. Example: For specimen 
collection, this may specify SOFT TISSUE. 
Perm 
BEBODSYS  Body System or Organ Class Char  *  Record 
Qualifier 
Body system or organ class used by the sponsor from the coding dictionary (e.g., 
MedDRA). When using a multi-axial dictionary such as MedDRA, this should 
contain the SOC used for the sponsor’s analyses and summary tables which may 
not necessarily be the primary SOC. 
Perm 
BELOC  Body Location  Char  (LOC)  Record 
Qualifier 
Describes body location relevant for the event (e.g. BRAIN, LUNG).  Perm 
BEPARENT  Specimen Parent  Char    Record 
Qualifier 
Identifies the parent of a specimen to support tracking its genealogy.  Perm 
BESPCLVL  Specimen Level  Num    Record 
Qualifier 
Identifies the generation number of the sample where the collected sample is 
considered the first generation. 
Perm 
VISITNUM  Visit Number  Num     Timing  1. Clinical encounter number. 2. Numeric version of VISIT, used for sorting.  Exp 
VISIT  Visit Name  Char    Timing  1. Protocol-defined description of clinical encounters. 2. May be used in addition 
to VISITNUM and/or VISITDY 
Perm 
VISITDY  Planned Study Day of Visit  Num    Timing  Planned study day of the visit based upon RFSTDTC in Demographics.  Perm 
BEDTC  Date/Time of Specimen 
Collection 
Char  ISO 8601   Timing  Date and time of specimen collection.  Exp 
BESTDTC  Start Date/Time of 
Biospecimen Event 
Char  ISO 8601   Timing  Start Date/Time of a biospecimen event.  Exp 
BEENDTC  End Date/Time of 
Biospecimen Event 
Char  ISO 8601   Timing  End Date/Time of a biospecimen event  Exp 
BESTDY  Study Day of Start of 
Biospecimen Event 
Num     Timing  Study day of start of biospecimen event relative to the sponsor-defined 
RFSTDTC. 
Perm 
BEENDY  Study Day of End of 
Biospecimen Event 
Num     Timing  Study day of end of event relative to the sponsor-defined RFSTDTC.   Perm 
BEDUR  Duration of Bio specimen 
Event 
Char  ISO 8601  Timing  Collected duration and unit of a biospecimen event. Used only if collected on the 
CRF and not derived from start and end date/times. Example: P1DT2H (for 1 
day, 2 hours). 
Perm 
* Indicates variable may be subject to controlled terminology, (Parenthesis indicates CDISC/NCI codelist code value) 
3.1.3 Assumptions for Biospecimen Events domain model 
1.  The BE domain contains data about actions taken that affect or may affect a specimen, such as specimen collection, freezing and thawing, aliquoting, 
and transportation.  
2.  Event timing consists primarily of start/end date/times and/or durations. 
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3.2 Biospecimen (BS) 
3.2.1 Description/Overview for Biospecimen Domain Model 
 The BS domain has no controlled terminology definition yet.  
 
--PARENT and --SPCLVL are variables for recording the hierarchy of specimen relationships. There is some question as to whether they belong in BE, BS, or as 
part of a special purpose relationships dataset (RELSPEC). For now, all three options are given.  
3.2.2 Specification for Biospecimen Domain Model 
bs.xpt, Biospecimen— Findings. One record per bio-specimen finding per specimen collected per subject, Tabulation 
Variable Name Variable Label  Type 
Controlled 
Terms, Codelist 
or Format 
Role  CDISC Notes  Core 
STUDYID  Study Identifier  Char     Identifier  Unique identifier for a study.  Req 
DOMAIN  Domain Abbreviation  Char  BS  Identifier  Two-character abbreviation for the domain.  Req 
USUBJID  Unique Subject Identifier  Char     Identifier  Identifier used to uniquely identify a subject across all studies for all applications 
or submissions involving the product. 
Req 
BSSEQ  Sequence Number  Num     Identifier  Sequence Number given to ensure uniqueness of subject records within a 
domain. May be any valid number.  
Req 
BSGRPID  Group ID  Char     Identifier  Used to tie together a block of related records in a single domain for a subject.  Perm 
BSREFID  Reference ID   Char    Identifier  Optional internal or external identifier such as lab specimen ID.  Perm 
SPDEVID  Sponsor Device Identifier  Char    Identifier  Sponsor-defined identifier for a device.  Perm 
BSSPID  Sponsor-Defined Identifier  Char    Identifier  Sponsor-defined reference number. Perhaps pre-printed on the CRF as an explicit 
line identifier or defined in the sponsor’s operational database. This may also be 
used to designate a sample derived from the collected specimen: Example: RNA 
or DNA extraction, tissue resectioning  
Perm 
BSTESTCD  Biospecimen Test or 
Examination Short Name 
Char  *  Topic  Short name of the measurement, test, observation or examination described in 
BSTEST. It can be used as a column name when converting a dataset from a 
vertical to a horizontal format. The value in BSTESTCD cannot be longer than 8 
characters, nor can it start with a number (e.g.'1TEST'). BSTESTCD cannot 
contain characters other than letters, numbers, or underscores. Examples: 
TISSTY, FLSFRZDT, ADDTIVOL 
Req 
BSTEST  Biospecimen Test or 
Examination Name 
Char  *  Synonym 
Qualifier 
Verbatim name of the test, observation or examination used to obtain the 
measurement or finding. Note any test normally performed by a clinical 
laboratory is considered a lab test. The value in BSTEST cannot be longer than 
40 characters. Examples: Flash Frozen Date Time, Flash Frozen Duration, 
Additive Volume 
Req 
BSCAT  Category for Biospecimen 
Test 
Char  *  Grouping 
Qualifier 
Used to define a category of related records across subjects. Example: 
SPECIMEN HANDLING, SPECIMEN MEASUREMENT  
Exp 
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Variable Name Variable Label  Type 
Controlled 
Terms, Codelist 
or Format 
Role  CDISC Notes  Core 
BSSCAT  Subcategory for 
Biospecimen Test 
Char  *  Grouping 
Qualifier 
A further categorization of a test category.  Perm 
BSORRES   Result or Finding in Original 
Units 
Char     Result 
Qualifier 
Result of the measurement or finding as originally received or collected.   Exp 
BSORRESU  Original Units  Char  *  Variable 
Qualifier  
Original units in which the data were collected. The unit for BSORRES. 
Examples: mg. or ml. 
Exp 
BSSTRESC  Character Result/Finding in 
Standard Format 
Char    Result 
Qualifier 
Contains the result value for all findings, copied or derived from BSORRES in a 
standard format or standard units. BSSTRESC should store all results or findings 
in character format; if results are numeric, they should also be stored in numeric 
format in BSSTRESN. For example, if a test has results 'NONE', 'NEG', and 
'NEGATIVE' in BSORRES and these results effectively have the same meaning, 
they may be represented in standard format in BSSTRESC as 'NEGATIVE'. 
Exp 
BSSTRESN  Numeric Result/Finding in 
Standard Units 
Num    Result 
Qualifier 
Used for continuous or numeric results or findings in standard format; copied in 
numeric format from BSSTRESC. BSSTRESN should store all numeric test 
results or findings. 
Exp 
BSSTRESU  Standard Units  Char  *  Variable 
Qualifier 
Standardized unit used for BSSTRESC or BSSTRESN.  Exp 
BSSTAT  Completion Status  Char  (ND)  Record 
Qualifier 
Used to indicate exam not done. Should be null if a result exists in BSORRES.   Perm 
BSREASND  Reason Test Not Done   Char    Record 
Qualifier 
Describes why a measurement or test was not performed such as BROKEN 
EQUIPMENT, SPECIMEN CONDITION or SPECIMEN LOST. Used in 
conjunction with BSSTAT when value is NOT DONE. 
Perm 
BSNAM  Vendor Name  Char    Record 
Qualifier 
The name or identifier of the laboratory that performed the test.  Perm 
BSSPEC  Specimen Type  Char  *  Record 
Qualifier 
Defines the type of specimen used for a measurement. Examples: SERUM, 
PLASMA, URINE, SOFT TISSUE. 
Perm 
BSPARENT  Specimen Parent  Char    Record 
Qualifier 
Identifies the parent of a specimen to support tracking its genealogy.  Perm 
BSSPCLVL  Specimen Level  Num    Record 
Qualifier 
Identifies the generation number of the sample where the collected sample is 
considered the first generation. 
Perm 
BSANTREG  Anatomical Region  Char  *  Variable 
Qualifier of 
BSSPEC 
 
Defines the specific anatomical or biological region of a tissue, organ specimen 
or the region from which the specimen is obtained, as defined in the protocol, 
such as a section or part of what is described in the --SPEC variable. Examples: 
CORTEX, MEDULLA, MUCOSA, CEREBRAL AQUEDECT  
Perm 
BSSPCCND  Specimen Condition  Char  *  Record 
Qualifier 
Free or standardized text describing the condition of the specimen.Examples: 
HEMOLYZED, ICTERIC, LIPEMIC. 
Perm 
BSMETHOD  Method of Test or 
Examination 
Char  *  Record 
Qualifier 
Method of the test or examination. Example: EXCISION  Perm 
BSRUNID  Run ID  Char    Record 
Qualifier 
A unique identifier for a particular run of a test on a particular batch of samples.  Perm 
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Variable Name Variable Label  Type 
Controlled 
Terms, Codelist 
or Format 
Role  CDISC Notes  Core 
BSBLFL  Baseline Flag  Char  (NY)  Record 
Qualifier 
Indicator used to identify a baseline value.  Exp 
VISITNUM  Visit Number  Num    Timing  1. Clinical encounter number.  
2. Numeric version of VISIT, used for sorting. 
Exp 
VISIT  Visit Name  Char    Timing  1. Protocol-defined description of clinical encounters.  
2. May be used in addition to VISITNUM and/or VISITDY 
Perm 
VISITDY  Planned Study Day of Visit  Num    Timing  Planned study day of the visit based upon RFSTDTC in Demographics.  Perm 
BSDTC  Date/Time of Specimen 
Collection 
Char  ISO 8601   Timing  Date/time of specimen collection   Exp 
BSSTDTC  Start Date/Time of Specimen 
Process 
Char  ISO 8601  Timing  Start Date/time of specimen handling process  Perm 
BSENDTC  End Date/Time of Specimen 
Process 
Char  ISO 8601  Timing  End Date/time of specimen handling process  Perm 
BSDY  Study Day of Specimen 
Collection 
Num    Timing  1. Study day of specimen collection, measured as integer days.  
2. Algorithm for calculations must be relative to the sponsor-defined RFSTDTC 
variable in Demographics. This formula should be consistent across the 
submission. 
Perm 
BSTPT  Planned Time Point Name  Char    Timing  1. Text Description of time when specimen should be taken.  
2. This may be represented as an elapsed time relative to a fixed reference point, 
such as time of last dose. See BSTPTNUM and BSTPTREF. Examples: Start, 5 
min post. 
Perm 
BSTPTNUM   Planned Time Point Number  Num    Timing  Numerical version of BSTPT to aid in sorting.   Perm 
BSELTM  Planned Elapsed Time from 
Time Point Ref 
Char  ISO 8601  Timing  Planned Elapsed time (in ISO 8601) relative to a planned fixed reference 
(BSTPTREF). This variable is useful where there are repetitive measures. Not a 
clock time or a date time variable. Represented as an ISO 8601 duration. 
Examples: '-PT15M' to represent the period of 15 minutes prior to the reference 
point indicated by BSTPTREF, or 'PT8H' to represent the period of 8 hours after 
the reference point indicated by BSTPTREF.  
Perm 
BSTPTREF  Time Point Reference   Char    Timing  Name of the fixed reference point referred to by BSELTM, if used for 
BSTPTNUM, and BSTPT. Examples: PREVIOUS DOSE, PREVIOUS MEAL. 
Perm 
BSRFTDTC    Char  ISO 8601  Timing  Date/time of the reference time point, BSTPTREF.  Perm 
* Indicates variable may be subject to controlled terminology, (Parenthesis indicates CDISC/NCI codelist code value) 
3.2.3 Assumptions for Biospecimen Domain Model 
1.  The BS domain is used to store findings related to specimen handling. It also contains specimen characteristics such as type, amount, or size. 
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3.3 Examples for Biospecimen Events and Biospecimen Domain Models 
Example 1 
Cell-free RNA, which can be obtained from plasma, may be useful for some tumor-specific cancer detection1, but has poor integrity2. In this example, a blood 
sample was drawn, centrifuged to get plasma, and treated with EDTA, and then the RNA was extracted and purified. The SPDEVID for the RNA purification kit 
is given in row 4. 
 
be.xpt 
Row  STUDYID  USUBJID  BESPDEVID  BESEQ  BEREFID  BETERM  BEDECOD  BECAT  BESCAT  VISITNUM  BEDTC  BESTDTC  BEENDTC 
1  3441271  MU-298    1  298B1  Collected  COLLECTED  COLLECTION  BLOOD  2  2010-04-01     
2  3441271  MU-298    2  298P1  Extraction  EXTRACTED  EXTRACTION  PLASMA         
            Treated  TREATED  PREP  PLASMA         
3  3441271  MU-298    3  298R1  Genetic Extraction  GENETIC  
EXTRACTION  EXTRACTION  RNA  2  2010-04-01     
4  3441271  MU-298  PURKIT  4  298R1  Purified  PURIFIED  PREP           
 
suppbe.xpt 
Row  STUDYID  RDOMAIN  USUBJID  IDVAR  IDVARVAL  QNAM  QLABEL  QVAL 
1  3441271  BE  AAA-XXX1  BETERM  Treated  TRT  Treatment  EDTA 
 
Example 2 
This is an example of volumetric measurements for specimens.  
 
bs.xpt 
Row  STUDYID  DOMAIN  USUBJID  BSSEQ  BSREFID  BSTESTCD  BSTEST  BSCAT  BSORRES  BSORRESU  BSSTRESC  BSSTRESN  BSSTRESU  BSBLFL  VISITNUM  BSDTC 
1  ISI1414  BS  XER01  1  1  VOLUME  Volume    10  mL  10  10  mL    3  2012-12-03 
2  ISI1414  BS  XER01  2  2  VOLUME  Volume    4  mL  4  4  mL    3  2012-12-03 
3  ISI1414  BS  XER01  3  1-1  VOLUME  Volume    3  mL  3  3  mL    3  2012-12-03 
4  ISI1414  BS  XER01  4  1-2  VOLUME  Volume    3  mL  3  3  mL    3  2012-12-03 
 
Example 3 
This example shows data about RNA integrity. 
 
bs.xpt 
Row  STUDYID  DOMAIN  USUBJID  BSSEQ  BSREFID  BSTESTCD  BSTEST  BSCAT  BSORRES  BSSTRESC  BSSTRESN  BSXFN 
1  A12345  BS  43871  1  1148.26704  A260A230  A260/A230  QC   2.05  2.05  2.05  2.16.090.1.135764.3.4:7280912 
2  A12345  BS  43871  2  1148.26704  A260A280  A260/A280  QC   2  2  2  2.16.090.1.135764.3.4:7280912 
3  A12345  BS  43871  3  1148.26704  I28S18S   28S/18S  QC   1.2  1.2  1.2  2.16.090.1.135764.3.4:7280912 
4  A12345  BS  43871  4  1148.26704  RIN  RNA INTEGRITY NUMBER  QC   9.5  9.5  9.5  2.16.090.1.135764.3.4:7280912 
5  A12345  BS  43871  5  1148.26704  CLSSCORE  Classifier Score  QC   0.4  0.4  0.4  2.16.090.1.135764.3.4:7280912 
1 Tsui NB, Ng EK, Lo YM. Molecular analysis of circulating RNA in plasma. Methods Mol Biol. 2006;336:123-34. 
2 Cerkovnik P, Perhavec A, Zgajnar J, Novakovic S. Optimization of an RNA isolation procedure from plasma samples. Int J Mol Med. 2007;20(3):293-300. 
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Row  BSNAM  BSMETHOD  BSRUNID  VISIT  VISITNUM  VISITDY  BSDTC 
1 (cont)  Deluxe Central Labs  SPECTROPHOTOMETRY  1000450001  Baseline  1  1  2005-03-21T11:28:17 
2 (cont)  Deluxe Central Labs  SPECTROPHOTOMETRY  1000450001  Baseline  1  1  2005-03-21T11:28:17 
3 (cont)  Deluxe Central Labs  ELECTROPHORESIS  1000450001  Baseline  1  1  2005-03-21T11:28:17 
4 (cont)  Deluxe Central Labs  ELECTROPHORESIS  1000450001  Baseline  1  1  2005-03-21T11:28:17 
5 (cont)  Deluxe Central Labs  BAYESIAN  1000450001  Baseline  1  1  2005-03-21T11:28:17 
 
Example 4  
In this example, a specimen is collected, flash frozen, thawed, and shipped to another location.  
 
Some tests are very sensitive to specimen handling processes such as flash freezing or time spent in transit. Therefore, it is important to record when the 
processes were started and completed. Such information goes is placed in the BE domain.  
 
Row 1:  Shows specimen collection.  
Rows 2-4:   Show the start and end date/times of flash freezing, storing while frozen, and thawing.  
Row 5:  Records the transportation of a biospecimen. The point of origination is not given because it is assumed to be the study site. 
 
be.xpt 
Row  STUDYID  DOMAIN  USUBJID  SPDEVID  BESEQ  BEREFID  BETERM  BEDECOD  BEPARTY  BEPRTYID  BECAT  BESCAT 
1  ABC134  BE  43871  TS409871  1  1148.267  Excision  EXCISION      COLLECTION  SOFT TISSUE 
2  ABC134  BE  43871    2  1148.267  Flash Frozen  FLASH FROZEN      PREP   
3  ABC134  BE  43871  309827  3  1148.267  Stored in Freezer  STORED      STORING   
4  ABC134  BE  43871    4  1148.267  Thaw  THAW      PREP   
5  ABC134  BE  43871  LN43871  5  1148.267  Shipped  SHIPPED  ABC LAB  01  TRANSPORT   
 
Row  BODSYS  BELOC  VISITNUM  VISIT  BEDTC  BESTDTC  BEENDTC 
1 (cont)  Nervous System [A08]  BRAIN  1  BASELINE  2005-02-20  2005-03-20T15:07   
2 (cont)  Nervous System [A08]  BRAIN  1  BASELINE  2005-03-20  2005-03-20T15:07  2005-03-20T13:22 
3 (cont)  Nervous System [A08]  BRAIN  1  BASELINE  2005-03-20  2005-03-20T13:22  2005-03-21T10:29 
4 (cont)  Nervous System [A08]  BRAIN  1  BASELINE  2005-03-21  2005-03-21T10:29  2005-03-21T10:36 
5 (cont)  Nervous System [A08]  BRAIN  1  BASELINE  2005-03-21  2005-03-21T11:00  2005-03-21T15:00 
 
Findings related to specimen handling processes are stored in BS. These processes are important to maintain the integrity of the specimens used in genetic 
variation and gene expression testing. Depending on how a study is designed, there might be very specific specimen handling specifications contained in the 
protocol for all labs to follow. Other protocols may let the labs determine the processes to follow. The examples below support the latter approach.  
 
Row 1:   Contains the volume of the biospecimen. 
Row 2:   Depicts the temperature to which the specimen was flash-frozen.  
 
bs.xpt 
Row  STUDYID  DOMAIN  USUBJID  BSSEQ  BSREFID  BSTESTCD  BSTEST  BSCAT  BSORRES  BSORRESU  BSSTRESC  BSSTRESN 
1  ABC134  BS  43871  1  1148.267  VOLUME  Volume  SPECIMEN MEASUREMENT  2  cm3  2  2 
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Row  STUDYID  DOMAIN  USUBJID  BSSEQ  BSREFID  BSTESTCD  BSTEST  BSCAT  BSORRES  BSORRESU  BSSTRESC  BSSTRESN 
2  ABC134  BS  43871  2  1148.267  FFRZTMP  Flash Frozen Temp  SPECIMEN HANDLING  -80  C  -80   
 
Row  BSSTRESU  BSPEC  BSANTREG  BSBLFL  VISITNUM  BSDTC 
1 (cont)  cm3  BRAIN  CEREBRAL AQUEDECT       
2 (cont)  C  BRAIN  CEREBRAL AQUEDECT  Y  1  2005-03-20 
 
RELREC relates the records in BE and BS to each other.  
 
Rows 1-2:  Tie the specimen volume to its collection 
Rows 3-4:  Tie the temperature at which the specimen was flash frozen to the event of its occurrence. 
 
relrec.xpt 
Row  STUDYID  RDOMAIN  USUBJID  IDVAR  IDVARVAL  RELTYPE  RELID 
1  ABC134  BE  43871  BESEQ  1    1 
2  ABC134  BS  43871  BSSEQ  1    1 
3  ABC134  BE  43871  BESEQ  2    2 
4  ABC134  BS  43871  BSSEQ  2    2 
 
3.4 Related Specimens 
There has been some question as to how to record specimen relationships and hierarchies, such as when a specimen is resectioned or aliquoted, and it is 
important to keep track of the chain of parent-child relationships back to the original collected specimen. One possibility would be to add two variables, --
PARENT, and --SPCLVL to the BE domain, or to the BS domain, or to both. Another method would be to create a special dataset specifically for the purpose of 
holding specimen relationship data, as given below.  
3.4.1 RELSPEC Dataset 
relrec.xpt, Related Specimens, Version 3.x.x. One record per specimen. 
Variable Name  Variable Label  Type 
Controlled 
Terms, Codelist 
or Format 
Role  CDISC Notes  Core 
STUDYID  Study Identifier  Char     Identifier  Unique identifier for a study.  Req 
USUBJID  Unique Subject Identifier  Char     Identifier  Identifier used to uniquely identify a subject across all studies for all applications 
or submissions involving the product. 
Req 
REFID  Specimen ID  Char     Identifier  Specimen identifier, unique within USUBJID.   Req 
SPEC  Specimen Type  Char  *  Record 
Qualifier 
Defines the type of specimen used for a measurement.  
Examples: SERUM, PLASMA, URINE, SOFT TISSUE. 
Perm 
PARENT  Specimen Parent  Char    Record 
Qualifier 
Identifies the parent of a specimen to support tracking its genealogy.  Exp 
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Variable Name  Variable Label  Type 
Controlled 
Terms, Codelist 
or Format 
Role  CDISC Notes  Core 
SPCLVL  Specimen Level  Num    Record 
Qualifier 
Identifies the generation number of the sample where the collected sample is 
considered the first generation. 
Req 
* Indicates variable may be subject to controlled terminology, (Parenthesis indicates CDISC/NCI codelist code value) 
3.4.2 Examples for Related Specimens 
The following examples all use the same sample specimen geneology, as illustrated below.  
 
Figure 1: Sample Specimen Relationship 
 
Any specimen with a BSSPCLVL value of “1” and a blank value for BSPARENT indicates a “collected sample”. All other values represent a “derived sample”. 
BSSPEC will always reflect the specimen type for the collected sample. BSGENSMP will be populated only for derived genetic samples. 
 
Example 1 
This example shows how the specimen genealogy might be represented in the BE domain.  
 
Row 1:  Specimen SPC-001 is the collected sample. 
Rows 2-3:  Specimen SPC-001 underwent a process to produce two derived samples “SPC-001-A” and “SPC-001-B”. BSPARENT indicates that “SPC-
001” is the immediate parent. Both derived samples contain a BSSPCLVL of “2” to indicate this is a second generation sample set derived from 
the collected sample. 
Row 4:   Specimen SPC-001-B is a DNA sample that was extracted from the derived sample SPC-001-, therefore it is considered a third generation 
(BSPSCLVL=”3”). 
Row 5:   This represents a second collected specimen.  
Row 6:   This RNA was extracted directly from the collected specimen so it has a second generation value of “2” in BSSPCLVL.  
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be.xpt 
Row  STUDYID  DOMAIN  USUBJID  BESEQ  BEREFID  BETERM  BEDECOD  BECAT  BESCAT  BEPARENT  BESPCLVL  … 
1  ABC-123  BS  001-01  1  SPC-001  Excision  EXCISION  COLLECTION  TISSUE    1  … 
2  ABC-123  BS  001-01  2  SPC-001-A  Resectioning  RESECTIONING  PREP  TISSUE  SPC-001  2  … 
3  ABC-123  BS  001-01  3  SPC-001-B  Resectioning  RESECTIONING  PREP  TISSUE  SPC-001  2  … 
4  ABC-123  BS  001-01  4  SPC-001-B-1  Genetic Extraction  GENETIC EXTRACTION  EXTRACTION  DNA  SPC-001-B  3  … 
5  ABC-123  BS  002-01  5  SPC-003  Excision  EXCISION  COLLECTION  BRAIN    1  … 
6  ABC-123  BS  002-01  6  SPC-003-A  Genetic Extraction  GENETIC EXTRACTION  EXTRACTION  RNA  SPC-003  2  … 
 
Example 2 
This example shows how the specimen genealogy might be represented in the BS domain. 
 
Row 1:  Specimen SPC-001 is the collected samples as indicated via BSSPCLVL = “1”. 
Rows 2-3:  Specimen SPC-001 underwent a process to produce two derived samples “SPC-001-A” and “SPC-001-B”. BSPARENT indicates that “SPC-
001” is the immediate parent. Both derived samples contain a BSSPCLVL of “2” to indicate this is a second generation sample set derived from 
the collected sample. 
Row 4:   Specimen SPC-001-B-1 is a DNA sample that was extracted from the derived sample SPC-001-B, therefore it is considered a third generation 
(BSPSCLVL=”3”). 
Row 5:   This represents a second collected specimen. We used “BRAIN” as the specimen type since this is a valid specimen for toxicology studies as 
commonly used by SEND. 
Row 6:   This RNA was extracted directly from the collected specimen so it has a second generation value of “2” in BSSPCLVL.  
 
bs.xpt 
Row  STUDYID  DOMAIN  USUBJID  BSSEQ  BSREFID  BSTESTCD  BSTEST  BSORRES  BSORRESU  …  BSSPEC  BSPARENT  BSSPCLVL  … 
1  ABC-123  BS  001-01  1  SPC-001  SPECVOL  Biospecimen Volume  100      TISSUE    1  … 
2  ABC-123  BS  001-01  2  SPC-001-A  SPECVOL  Biospecimen Volume  50      TISSUE  SPC-001  2  … 
3  ABC-123  BS  001-01  3  SPC-001-B  SPECVOL  Biospecimen Volume  50      TISSUE  SPC-001  2  … 
4  ABC-123  BS  001-01  4  SPC-001-B-1  SPECVOL  Biospecimen Volume        DNA  SPC-001-B  3  … 
5  ABC-123  BS  002-01  5  SPC-003  SPECVOL  Biospecimen Volume  100      BRAIN    1  … 
6  ABC-123  BS  002-01  6  SPC-003-A  SPECVOL  Biospecimen Volume        RNA  SPC-003  2  … 
 
Example 3 
This example shows how the specimen genealogy might be represented in the RELSPEC dataset.  
 
Row  STUDYID  USUBJID  REFID  SPEC  PARENT  SPCLVL 
1  ABC-123  001-01  SPC-001  TISSUE    1 
2  ABC-123  001-01  SPC-001-A  TISSUE  SPC-001  2 
3  ABC-123  001-01  SPC-001-B  TISSUE  SPC-001  2 
4  ABC-123  001-01  SPC-001-B-1  DNA  SPC-001-B  3 
5  ABC-123  001-01  SPC-003  BRAIN    1 
6  ABC-123  001-01  SPC-003-A  RNA  SPC-003  2 
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6 Domain Models Based on the General 
Observation Classes 
6.3 Findings 
Nervous System Findings (NV) 
NV - Description/Overview for Nervous System Findings Domain Model 
A domain for physiological findings related to the nervous system, including the brain, spinal cord, the cranial and spinal nerves, autonomic ganglia and 
plexuses. 
 
The NV domain is still in the very early stages of development.  
NV - Specification for Nervous System Findings Domain Model 
nv.xpt, Nervous System Findings — Findings, Version 3.3. One record per Nervous System Findings finding per location per time point per visit per 
subject, Tabulation 
Variable Name  Variable Label  Type  Controlled Terms, 
Codelist or Format  Role  CDISC Notes  Core 
STUDYID  Study Identifier  Char     Identifier  Unique identifier for a study.  Req 
DOMAIN  Domain Abbreviation  Char 
1930HNV  Identifier  Two-character abbreviation for the domain.  Req 
USUBJID  Unique Subject Identifier  Char     Identifier  Identifier used to uniquely identify a subject across all studies for all 
applications or submissions involving the product. 
Req 
NVSEQ  Sequence Number  Num     Identifier  Sequence Number given to ensure uniqueness of subject records 
within a domain. May be any valid number.  
Req 
NVGRPID  Group ID  Char     Identifier  Used to tie together a block of related records in a single domain for a 
subject. 
Perm 
NVREFID  Reference ID  Char     Identifier  Internal or external procedure identifier.   Perm 
NVSPID  Sponsor-Defined Identifier  Char    Identifier  Sponsor-defined reference number. Perhaps pre-printed on the CRF as 
an explicit line identifier or defined in the sponsor's operational 
database. Example: Line number from the procedure or test page. 
Perm 
NVLNKID  Link ID   Char    Identifier   Identifier used to link a procedure to the assessment results over the 
course of the study.  
Perm 
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Variable Name  Variable Label  Type  Controlled Terms, 
Codelist or Format  Role  CDISC Notes  Core 
NVTESTCD  Test or Examination Short 
Name 
Char  *  Topic  Short name of the measurement, test, or examination described in 
NVTEST. It can be used as a column name when converting a dataset 
from a vertical to a horizontal format. The value in NVTESTCD 
cannot be longer than 8 characters, nor can it start with a number (e.g., 
“1TEST”). NVTESTCD cannot contain characters other than letters, 
numbers, or underscores. Example: SUVR 
Req 
NVTEST  Test or Examination Name  Char  *  Synonym 
Qualifier 
Verbatim name of the test or examination used to obtain the 
measurement or finding. The value in NVTEST cannot be longer than 
40 characters. Example: Standard Uptake Value Ratio, etc. 
 
Req 
NVCAT  Category for Test  Char  *  Grouping 
Qualifier 
Used to categorize observations across subjects.   Perm 
NVSCAT  Subcategory for Test  Char  *  Grouping 
Qualifier 
A further categorization.  Perm 
NVPOS  Position of Subject  Char  (POSITION)  Record 
Qualifier 
Position of the subject during a measurement or examination. 
Examples: SUPINE, STANDING, SITTING. 
Perm 
NVORRES  Result or Finding in Original 
Units 
Char    Result 
Qualifier 
Result of the procedure measurement or finding as originally received 
or collected.  
Exp 
NVORRESU  Original Units  Char  (UNIT)  Variable 
Qualifier  
Original units in which the data were collected. The unit for 
NVORRES.  
Perm 
NVSTRESC  Character Result/Finding in 
Std Format 
Char    Result 
Qualifier 
Contains the result value for all findings, copied or derived from 
NVORRES in a standard format or standard units. NVSTRESC 
should store all results or findings in character format; if results are 
numeric, they should also be stored in numeric format in NVSTRESN.  
Exp 
NVSTRESN  Numeric Result/Finding in 
Standard Units 
Num     Result 
Qualifier 
Used for continuous or numeric results or findings in standard format; 
copied in numeric format from NVSTRESC. NVSTRESN should 
store all numeric test results or findings. 
Perm 
NVSTRESU  Standard Units  Char  (UNIT)  Variable 
Qualifier 
Standardized unit used for NVSTRESC or NVSTRESN.   Perm 
NVSTAT  Completion Status  Char  (ND)  Record 
Qualifier 
Used to indicate a test was not done, or a measurement was not taken. 
Should be null if a result exists in NVORRES.  
Perm 
NVREASND  Reason Test Not Performed  Char     Record 
Qualifier 
Describes why a measurement or test was not performed. Examples: 
BROKEN EQUIPMENT or SUBJECT REFUSED. Used in 
conjunction with NVSTAT when value is NOT DONE. 
Perm 
NVXFN  Raw Data File 
 
Char     Record 
Qualifier 
Filename for an external file used to populate the NV domain.   Perm 
NVNAM  Laboratory/Vendor Name   Char    Record 
Qualifier 
Name or identifier of the vendor (e.g., laboratory) that provided the 
test results.  
 
Perm 
© 2013 Clinical Data Interchange Standards Consortium, Inc. All rights reserved   NV - Page 2 
Draft  December 6, 2013 CDISC SDTM Implementation Guide (Version 3.3) 
Variable Name  Variable Label  Type  Controlled Terms, 
Codelist or Format  Role  CDISC Notes  Core 
NVLOC  Location Used for 
Measurement 
Char  (LOC)  Record 
Qualifier 
  Perm 
NVLAT  Specimen Laterality within 
Subject 
Char  (LAT)  Variable 
Qualifier 
Qualifier for laterality of the specimen within the subject for paired 
specimens.  Examples: LEFT, RIGHT, BILATERAL. 
Perm 
NVDIR  Specimen Directionality 
within Subject 
Char  (DIR)  Variable 
Qualifier 
Qualifier for directionality of the specimen within the subject.  
Examples: DORSAL, PROXIMAL. 
Perm 
NVMETHOD  Method of Procedure Test   Char  (METHOD)  Record 
Qualifier 
Method of the procedure.  Perm 
NVBLFL  Baseline Flag  Char  (NY)  Record 
Qualifier 
Indicator used to identify a baseline value. The value should be “Y” or 
null. 
Exp 
NVDRVFL  Derived Flag  Char  (NY)  Record 
Qualifier 
Used to indicate a derived record. The value should be Y or null. Records 
which represent the average of other records, or that do not come from the 
CRF, or are not as originally collected or received are examples of records that 
would be derived for the submission datasets. If NVDRVFL=Y, then 
NVORRES would be null, with, and (if numeric) NVSTRESN having the 
derived value. 
Perm 
NVEVAL  Evaluator  Char  *  Record 
Qualifier 
Role of the person who provided the evaluation. Used only for results 
that are subjective (e.g., assigned by a person or a group). Should be 
null for records that contain collected or derived data. Examples: 
INVESTIGATOR, ADJUDICATION COMMITTEE, VENDOR. 
Perm 
VISITNUM  Visit Number  Num     Timing  1. Clinical encounter number.  
2. Numeric version of VISIT, used for sorting. 
Exp 
VISIT  Visit Name  Char     Timing  1. Protocol-defined description of clinical encounter.  
2. May be used in addition to VISITNUM and/or VISITDY.  
Perm 
VISITDY  Planned Study Day of Visit  Num     Timing  Planned study day of the visit based upon RFSTDTC in 
Demographics. 
Perm 
NVDTC  Date/Time of Test  Char  ISO 8601   Timing  Date of procedure or test.  Exp 
NVDY  Study Day of Test   Num     Timing  1. Study day of the procedure or test, measured as integer days.  
2. Algorithm for calculations must be relative to the sponsor-defined 
RFSTDTC variable in Demographics.  
Perm 
NVTPT  Planned Time Point Name  Char     Timing  1. Text Description of time when measurement should be taken.  
2. This may be represented as an elapsed time relative to a fixed 
reference point, such as time of last dose. See NVTPTNUM and 
NVTPTREF. Examples: Start, 5 min post. 
Perm 
NVTPTNUM  Planned Time Point Number  Num     Timing  Numerical version of NVTPT to aid in sorting.   Perm 
NVELTM  Planned Elapsed Time from 
Time Point Ref 
Char  ISO 8601  Timing  Planned elapsed time (in ISO 8601) relative to a fixed time point reference 
(NVTPTREF). Not a clock time or a date time variable. Represented as an 
ISO 8601 duration. Examples: “-PT15M” to represent the period of 15 
minutes prior to the reference point indicated by NVTPTREF, or “PT8H” 
to represent the period of 8 hours after the reference point indicated by 
NVTPTREF. 
Perm 
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Variable Name  Variable Label  Type  Controlled Terms, 
Codelist or Format  Role  CDISC Notes  Core 
NVTPTREF  Time Point Reference   Char     Timing  Name of the fixed reference point referred to by NVELTM, 
NVTPTNUM, and NVTPT. Examples: PREVIOUS DOSE, 
PREVIOUS MEAL. 
Perm 
NVRFTDTC  Date/Time of Reference Time 
Point 
Char  ISO 8601  Timing  Date/time of the reference time point, NVTPTREF.  Perm 
* Indicates variable may be subject to controlled terminology (Parenthesis indicates CDISC/NCI codelist code value) 
NV - Assumptions for Nervous System Findings Domain Model 
1.  NV Definition: This domain has been designed to store data on neurological physiological findings that include information relating to the brain, the 
spinal cord, and the nerves. 
2.  Additional Findings Qualifiers 
a.  The following variables would not generally be used in NV: --LOINC, --FAST, --TOX, --TOXGR.  
NV - Examples for Nervous System Findings Domain Model 
 
Example 1 
This example shows measures for standard uptake value ratios taken from three PET scans. NVDTC corresponds to the date of the PET or PET/CT procedure 
from which these results were obtained. 
 
Rows 1-2:   Show the Standard Uptake Value Ratio (SUVR) findings based on a PET/CT scan for subject AD01-101.  
Rows 3-4:  Show the SUVR findings based on a PET/CT scan for subject AD01-102. 
Rows 5-6:  Show the SUVR findings based on an FDG-PET scan for subject AD AD01-103. 
 
nv.xpt 
Row  STUDYID  DOMAIN  USUBJID  SPDEVID  NVSEQ  NVREFID  NVLNKID  NVTESTCD  NVTEST  NVORRES  NVORRESU 
1  ABC123  NV  AD01-101  22  1  1236  03  SUVR  Standard Uptake Value Ratio  .95  RATIO 
2  ABC123  NV  AD01-101  22  2  1236  03  SUVR  Standard Uptake Value Ratio  1.17  RATIO 
3  ABC123  NV  AD01-102  22  1  1237  04  SUVR  Standard Uptake Value Ratio  1.21  RATIO 
4  ABC123  NV  AD01-102  22  2  1237  04  SUVR  Standard Uptake Value Ratio  1.78  RATIO 
5  ABC123  NV  AD01-103  44  1  1238  05  SUVR  Standard Uptake Value Ratio  1.52  RATIO 
6  ABC123  NV  AD01-103  44  2  1238  05  SUVR  Standard Uptake Value Ratio  1.63  RATIO 
 
Row  NVSTRESC  NVSTRESN  NVSTRRESU  NVLOC  NVDIR  NVMETHOD  NVDTC 
1 (cont)  .95  .95  RATIO  PRECUNEUS    PET/CT SCAN  2012-05-22 
2 (cont)  1.17  1.17  RATIO  CINGULATE CORTEX  POSTERIOR  PET/CT SCAN  2012-05-22 
3 (cont)  1.21  1.21  RATIO  PRECUNEUS    PET/CT SCAN  2012-05-22 
4 (cont)  1.78  1.78  RATIO  CINGULATE CORTEX  POSTERIOR  PET/CT SCAN  2012-05-22 
5 (cont)  1.52  1.52  RATIO  PRECUNEUS    FDGPET  2012-05-22 
6 (cont)  1.63  1.63  RATIO  CINGULATE CORTEX  POSTERIOR  FDGPET  2012-05-22 
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A supplemental qualifiers dataset is used for additional data elements that are not part of the NV domain. 
 
Rows 1-6:   Shows the reference region used for the SUVR tests shown in the NV domain.  
 
suppnv.xpt 
Row  STUDYID  RDOMAIN  USUBJID  IDVAR  IDVARVAL  QNAM  QLABEL  QVAL 
1  ABC123  NV  AD01-101  NVSEQ  1  REFREG  Reference Region  CEREBELLUM 
2  ABC123  NV  AD01-101  NVSEQ  2  REFREG  Reference Region  CEREBELLUM 
3  ABC123  NV  AD01-102  NVSEQ  1  REFREG  Reference Region  CEREBELLUM 
4  ABC123  NV  AD01-102  NVSEQ  2  REFREG  Reference Region  CEREBELLUM 
5  ABC123  NV  AD01-103  NVSEQ  1  REFREG  Reference Region  PONS 
6  ABC123  NV  AD01-103  NVSEQ  2  REFREG  Reference Region  PONS 
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4 Pharmacogenomics/Genetics Domains 
4.1 Pharmacogenomics Findings (PF) 
The Pharmacogenomics Findings (PF) domain is a findings domain for gene expression and genetic variation assessments.  
 
--TESTCV, --TCVNM, and --TSCVVR comprise a set of variables that propose to hold external terminology for a given --TEST, so that individual variables 
need not be created for each possible dictionary or database (such as the --LOINC variable). --RESCV, --RCVNM, and RCVVR comprise a comparable set of 
variables for results. 
 
PFSPCIES and PFSTRAIN are proposed variables for recording the species and strain of a subject’s pathogen (such as a virus) when that pathogen comes under 
study.  
 
PFGENTYP, PFGENRI, and PFGENSRI are variables used to further identify the specific portion of the genome being tested. For genetic variation, 
PFREFSEQ, PFGENLOC, PFORRES and PFORREF hold individual aspects of the variation recorded, which is given in HGVS nomenclature in PFSTRESC, 
while PFMUTYP is used to record whether the variation is inheritable or arising only in parts of the body such as in cancerous tumors.  
4.1.1 Specification for Pharmacogenomics Findings Domain Model 
pf.xpt, Pharmacogenomics Findings - Findings. One record per method/setup observation per specimen collected per date of test per subject, 
Tabulation 
Variable Name  Variable Label  Type 
Controlled 
Terms, Codelist 
or Format 
Role  CDISC Notes  Core 
STUDYID  Study Identifier  Char    Identifier  Unique identifier for a study within the submission.  Req 
DOMAIN  Domain Abbreviation  Char  PF   Identifier  Two-character abbreviation for the domain most relevant to the observation.  Req 
USUBJID  Unique Subject Identifier  Char    Identifier  Unique subject identifier within the submission.  Req 
SPDEVID  Sponsor Device Identifier  Char    Identifier  Sponsor-defined identifier for a device.  Perm 
PFSEQ  Sequence Number  Num    Identifier  Sequence number given to ensure uniqueness within a dataset for a subject. Can 
be used to join related records. 
Req 
PFGRPID  Group ID  Char    Identifier  Used to tie together a block of related records in a single domain to support 
relationships within the domain and between domains. Example: drug 
metabolism link to PK data domain or grouping results related to one test; 
NS5B_71 where NS5B is the mutation and 71 is the position of the codon or just 
a numeric assign to group the records. 
Perm 
PFREFID  Reference ID   Char    Identifier  Optional internal or external identifier such as lab specimen ID.  Perm 
PFSPID  Sponsor ID  Char    Identifier  Sponsor-defined identifier.  Perm 
PFLNKID  Link ID  Char    Identifier  Supports linking information across different domains.  Perm 
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PFTESTCD  Genomics Test Short Name  Char  *  Topic  Short name for the test. Examples: AA, NUC, ALE, GENOTYPE, PVAL, 
FOLDCHG. 
Req 
PFTEST  Genomics Test Name  Char  *  Synonym 
Qualifier 
The verbatim name used to obtain the measurement or finding. Examples: 
Amino Acid, Nucleotide, Allele, Genotype, P Value, Fold Change. 
Perm 
PFTESTCV  Genomics Test Controlled 
Vocabulary 
Char  *  Synonym 
Qualifier 
A code or identifier for the test. The length of this variable can be longer than 8 to 
accommodate the length of the external terminology. Example: 48019-4. 
Perm 
PFTCVNM  Name of the Vocab for the 
Test 
Char    Result 
Qualifier 
The name of the terminology from which PFTESTCV is taken. Examples: 
SNOMED, LOINC. 
Perm 
PFTCVVR  Version of the Vocab for the 
Test 
Char    Result 
Qualifier 
The version of the terminology, if applicable.  Perm 
PFGENTYP  Genetic Region of Interest 
Type 
Char  *  Result 
Qualifier 
Identifies the type of genetic region of interest. Examples: GENE, SECTOR, 
PROTEIN. 
Exp 
PFGENRI  Genetic Region of Interest  Char  *  Result 
Qualifier 
Area within the DNA sequences. Example: EGFR, CIC, KRAS  Exp 
PFGENSRI  Genetic Sub-Region of 
Interest 
Char  *  Result 
Qualifier 
Area within the DNA sequences that is contained within the region identified by 
PFGENRI. Example: PROTEASE 
Perm 
PFSPCIES  Biological Classification  Char  *  Grouping 
Qualifier 
Biological classifications for an organism capable of breeding and producing 
offspring. Examples: BACTERIUM, HCV, HIV 
Perm 
PFSTRAIN  Type of Strain  Char  *  Grouping 
Qualifier 
A genetic variant or subtype of a microorganism. Examples: 1a, 1b.  Perm 
PFCAT  Category for 
Pharmacogenomics Lab Test 
Char  *  Grouping 
Qualifier 
Used to categorize types of genetic/genomic tests. Examples: GENETIC 
VARIATION, GENE EXPRESSION 
Exp 
PFSCAT  Subcategory for 
Pharmacogenomics Lab Test 
Char  *  Grouping 
Qualifier 
A further categorization of the various test types based on particular 
characteristics of a test. Examples: INTERPRETATION, PHENOTYPIC 
EXPRESSION 
Perm 
PFGENLOC  Genetic Location  Char    Result 
Qualifier 
Specifies a location within a sequence pertaining to the observed results 
contained in PFORRES, PFSTRESC and PFSTRESN. 
Perm 
PFORRES  Result or Finding in Original 
Units 
Char    Result 
Qualifier 
Result of the measurement or finding as originally received or collected. 
Examples: T, Gly, del. 
Exp 
PFORRESU  Original Units  Char    Variable 
Qualifier 
Represents the unit of measure used by PFORRES, if applicable. Examples: 
copies/5uL, LOG10 IU/ml, Cycles 
Perm 
PFORREF  Reference Result  Char    Variable 
Qualifier 
Reference result for the measurement or finding, in the same format as 
PFORRES. PFORREF uses the same units as PFORRES, if applicable. 
Perm 
PFSTRESC  Result or Finding in 
Standard Format 
Char    Result 
Qualifier 
Contains the result value for all findings, copied or derived from PFORRES in a 
standard format or in standard units. PFSTRESC should store all results or 
findings in character format; if results are numeric, they should also be stored in 
numeric format in PFSTRESN. 
Exp 
PFSTRESN  Numeric Result/Finding in 
Standard Units 
Num    Result 
Qualifier 
Used for continuous or numeric results or findings in standard format; copied in 
numeric format from PFSTRESC. PFSTRESN should store all numeric test 
results or findings. Example: for P-Value; 0.5391 
Perm 
PFSTRESU  Standard Units  Char  (UNIT)  Variable 
Qualifier 
Standardized units used for PFSTRESC and PFSTRESN.  Perm 
PFREFSEQ  Reference Sequence  Char  *  Variable 
Qualifier 
A unique identifier for the reference sequence used to identify the genetic variation. 
Examples: NM_001234, rs02973492 
Perm 
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PFRESCV  Genomics Result Controlled 
Vocabulary 
Char  *  Result 
Qualifier 
A code or identifier for the result in PFSTRESC. The length of this variable can be 
longer than 8 to accommodate the length of the external terminology. Examples: 
Arg, C49488, rs1042522. 
Perm 
PFRCVNM  Name of the Vocab for the 
Result 
Char    Result 
Qualifier 
The name of the terminology or database from which PFRESCV is taken. 
Examples: HGVS, dbSNP 
Perm 
PFRCVVR  Version of the Vocab for the 
Result 
Char    Result 
Qualifier 
The version of the terminology, if applicable.  Perm 
PFRESCAT  Result Category  Char  *  Result 
Qualifier 
Used to categorize the result of a finding. Example: RESISTANCE VARIANT.  Perm 
PFMUTYP  Mutation Type  Char  *  Grouping 
Qualifier 
Indicates whether a mutation is inheritable or not. Examples: SOMATIC, 
GERMLINE 
Perm 
PFSTAT  Test Status  Char  (ND)  Record 
Qualifier 
Used to indicate exam not done. Should be null if a result exists in PFSTRESC.  Perm 
PFREASND  Reason Test Not Done  Char    Record 
Qualifier 
Describes why a measurement or test was not performed such as BROKEN 
EQUIPMENT, SUBJECT REFUSED, or SPECIMEN LOST. Used in 
conjunction with PFSTAT when value is NOT DONE. 
Perm 
PFXFN  Raw Data File or Life 
Science Identifier 
Char    Record 
Qualifier 
Direct reference identifier for Microarray or Genotypic data contained in a 
separate file in its native format. 
Perm 
PFNAM  Vendor Name  Char    Record 
Qualifier 
Name or identifier of the laboratory or biotech firm who provides the test results.  Perm 
PFSPEC  Specimen Type  Char  *  Record 
Qualifier 
Defines the type of specimen used for a measurement. Examples: DNA, RNA  Perm 
PFSPCCND  Specimen Condition  Char    Record 
Qualifier 
Free or standardized text describing the condition of the specimen. Example: 
CONTAMINATED 
Perm 
PFMETHOD  Method Code for Test  Char  (METHOD)  Record 
Qualifier 
Special instructions for the execution of genomics or genetic testing. Examples: 
SNPASSAY, CLIP SEQUENCING, PYROSEQUENCING, BICHROME GENE 
EXPRESSION CHIP). 
Req 
PFRUNID  Run ID  Char    Record 
Qualifier 
A unique identifier for a particular run of a test on a particular batch of samples.  Perm 
PFANMETH  Analysis Method  Char  *  Record 
Qualifier 
Analysis method applied to obtain a summarized result. Analysis method 
describes the method of secondary processing applied to a complex observation 
result (e.g. an image or a genetic sequence). 
Perm 
PFBLFL  Baseline Flag  Char  (NY)  Record 
Qualifier 
Indicator used to identify a baseline value.  Exp 
PFDRVFL  Derived Flag  Char  (NY)  Record 
Qualifier 
Used to indicate a derived record.  Perm 
VISITNUM  Visit Number  Num    Timing  1. Clinical encounter number.  
2. Numeric version of VISIT, used for sorting. 
Exp 
VISIT  Visit Name  Char    Timing  1. Protocol-defined description of clinical encounter.  
2. May be used in addition to VISITNUM and/or VISITDY 
Perm 
VISITDY  Planned Study Day of Visit  Num    Timing  Planned study day of the visit based upon RFSTDTC in Demographics.  Perm 
PFDTC  Date/Time of Specimen 
Collection 
Char  ISO 8601  Timing  Date/time of specimen collection  Exp 
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PFDY  Study Day of Specimen 
Collection 
Num    Timing  1. Study day of specimen collection, measured as integer days.  
2. Algorithm for calculations must be relative to the sponsor-defined RFSTDTC 
variable in Demographics. This formula should be consistent across the 
submission. 
Perm 
PFTPT  Planned Time Point Name  Char    Timing  1. Text Description of time when specimen should be taken.  
2. This may be represented as an elapsed time relative to a fixed reference point, 
such as time of last dose. See PFTPTNUM and PFTPTREF. Examples: Start, 5 
min post. 
Perm 
PFTPTNUM  Planned Time Point Number  Num    Timing  Numerical version of PFTPT to aid in sorting.  Perm 
PFELTM  Elapsed Time from 
Reference Point 
Char  ISO 8601  Timing  Elapsed time (in ISO 8601) relative to a planned fixed reference (PFTPTREF). 
This variable is useful where there are repetitive measures. Not a clock time or a 
date time variable. Examples: '-P15M' to represent the period of 15 minutes prior 
to the reference point indicated by PFTPTREF, or 'P8H' to represent the period of 
8 hours after the reference point indicated by PFTPTREF. 
Perm 
PFTPTREF  Time Point Reference  Char    Timing  Name of the fixed reference point referred to by PFELTM, PFTPTNUM, and 
PFTPT. Examples: PREVIOUS DOSE, PREVIOUS MEAL. 
Perm 
PFRFTDTC  Date/Time of Reference 
Time Point 
Char  ISO 8601  Timing  Date/time of the reference time point, PFTPTREF.  Perm 
* Indicates variable may be subject to controlled terminology, (Parenthesis indicates CDISC/NCI codelist code value) 
4.1.2 Assumptions for Pharmacogenomics Findings domain model 
1.  PF captures results for genetic variation and gene expression. Genetic variation results are indicated by a PFCAT value of GENETIC VARIATION. 
Gene expression results are indicated by a PFCAT value of GENE EXPRESSION.  
2.  This domain is for clinical and pre-clinical use, for tests on a study subject or on an infectious microbe. 
3.  PFRUNID is used to distinguish between records for the same genetic test performed using different assays. When a genetic test is performed on an 
individual subject using multiple assays, the combination of PFNAM, PFRUNID and REFID may be necessary to obtain the full set of genomic data 
produced and sent by the lab for a specific test. This can facilitate delivering additional information to regulatory agencies, if needed. 
4.  PFMETHOD lists techniques for the execution of genomics or genetic testing. 
5.  Somatic/germline is determined by where the sample came from. Mutations found in tumor tissue but not found in a sample part of the body not 
affected by cancer (often using a check scraping) are considered somatic. Mutations found in the “control” sample from a non-tumor part of the body are 
considered germline.  
6.  Calculations: 
a.  When the sponsor performs a calculation, the value for PFDRVFL should be set to “Y”. If PFDRVFL is null, then any calculations have been 
performed by the vendor.  
b.  Only the p-value calculations that are performed by the lab should be included in PF.  
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7.  Viral Findings:  
a.  When using the pharmacogenomics domains for viral test reporting, the identification of the virus requires the virus name be placed in the 
PFSPCIES variable and if available, the strain is placed in PFSTRAIN field. PFSPCIES and PFSTRAIN should not be used for the species and 
strain of study subjects.  
b.  Because viruses only have inheritable DNA, for viral findings, mutation type (PFMUTYP) should always be “GERMLINE”. 
8.  Genetic Variation: 
a.  Unless a test is looking for a specific mutation, PFTESTCD and PFTEST generally specify the type of material assessed, such as nucleic acid, 
amino acid, or codon. 
b.  PFSCAT is used to categorize the tests, for example, AMINO ACID, MUTATION, and IDENTIFIER.  
c.  Results in PFSTRESC use HGVS nomenclature.  
i.  Results from sequencing of the whole gene include the gene’s reference sequence accession number. Example: NM_1234c.567A>C 
ii.  Results of targeted tests report only the targeted change, not including the initial code that indicates the gene. Example: c.567A>C 
d.  When results indicate a mixture of genetic results, as when comparing chromosomes, the results in PFORRES should be concatenated using 
slashes. For example, “C/T” at a nucleotide position indicates that the subject has heterozygous alleles. 
 
4.1.3 Examples for Pharmacogenomics Findings Domain Model 
This copy of the PF domain contains an abbreviated number of examples.  
 
Example 1 
This example shows a submission for viral genetics which reports amino acid observations only, without identifying the nucleotide variation that caused it.  
 
Row  STUDYID  DOMAIN  USUBJID  PFSEQ  PFREFID  PFGENTYP  PFGENRI  PFTESTCD  PFTEST  PFSPCIES  PFSTRAIN  PFCAT  PGGENLOC 
1  P7081-5101  PF  P7081-5101-01201  1  ABC-001  PROTEIN  NS5B  AA  Amino Acid  HCV  1a  GENETIC VARIATION  65 
 
Row  PFORRES  PFORREF  PFSTRESC  PFREFSEQ  PFRESCAT  PFMUTYP  PFNAM  PFMETHOD  PFBLFL  VISITNUM  VISIT  VISITDY  PFDTC 
1 
(cont)  R  Gln  NC_00472.1:p.Gln65Arg  NC_00472.1  Point 
Mutation  GERMLINE  Acme 
Genetics 
Massively Parallel 
Sequencing  Y  1  Baseline  1  2003-03-
27 
 
Example 2 
This viral genetics example contains both amino acid observations and their underlying mutations being reported at the codon level.  
 
Row 2:  Shows the amino acid that resulted from the mutation.  
Row 3:  Reports the genetic mutation at the codon level. Because HGVS nomenclature does not support reporting at the codon level, PFSTRESC holds the 
nucleotide variation.  
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Row  STUDYID  DOMAIN  USUBJID  PFSEQ PFGRPID PFREFID GENTYP PFGENRI PFTESTCD  PFTEST  PFSPCIES PFSTRAIN  PFCAT  PFGENLOC 
1  P7081-5101  PF  P7081-5101-06891  5  NS5B_71  ABC-003  PROTEIN  NS5B  AA  Amino Acid  HCV  1a  GENETIC VARIATION  71 
2  P7081-5101  PF  P7081-5101-06891  7  NS5B_71  ABC-003  PROTEIN  NS5B  CDN  Codon  HCV  1a  GENETIC VARIATION  213_215 
 
Row  PFORRES  PFSTRESC  PFORREF PFREFSEQ  PFNAM  PFSPEC  PFMETHOD  PFBLFL PFDRVFL VISITNUM  VISIT  VISITDY  PFDTC 
1 (cont)  Ile  NC_00472.1:p.Val71Ile  Val  NC_00472.1 Acme Genetics  DNA  Pyrosequencing  Y  Y  1  Baseline  1  2003-03-27 
2 (cont)  ATT  NM_005678:c.213A>G  GTT  NC_00472.1 Acme Genetics  DNA  Pyrosequencing  Y    1  Baseline  1  2003-03-27 
 
Example 3 
A frame shift occurs when an insertion or deletion (or both) occurs between the first (initiation (ATG)) and last (termination, stop (TAA, TAG, or TGA)) codon, 
replacing the normal C-terminal sequence with one encoded by another reading frame*. The effect can be akin to a phrase that reads: “THE OGA TET HER ATF 
ORT HEC ATW AST OOF AT” because the letter D has been eliminated from the fourth position†. Frame shifts can also drastically alter the length of the 
coding sequence.  
 
 
Figure 1: Frame Shift Comparison 
 
* den Dunnen J. Recommendations for the description of protein sequence variants (v2.0). Human Genome Variation Society. October 11, 2013. Available at: http://www.hgvs.org/mutnomen/recs-
prot.html. Accessed December 9, 2013. 
† The proper phrase, from which D has not been deleted in position 4, would be: “THE DOG ATE THE RAT FOR THE CAT WAS TOO FAT”. 
© 2013 Clinical Data Interchange Standards Consortium, Inc. All rights reserved    Page 6 
Draft     December 16, 2013 
                                                            CDISC SDTM Pharmacogenomics/Genetics Implementation Guide (Version 1.0 Draft) 
 
This example shows a frame shift found in a virus, and one found in a study subject. Note that in the first two rows, which hold viral genetic data, PFSPCIES and 
PFSTRAIN have been populated with the virus’s species and strain. The second two rows hold data for the the subject, and so PFSPCIES and PFSTRAIN are 
null.  
 
Row 2:   Shows a frame shift itself discovered in the HCV 1a virus carried by subject P341-5101-06345.  
Row 1:  Shows the nucleotide deletion which caused the frame shift. 
Rows 3-4:  Show a frame shift and its cause for subject P341-5101-06345, the virus’s host.  
 
pf.xpt 
Row  STUDYID  DOMAIN  USUBJID  PFSEQ  PFREFID  PFGENTYP  PFGENRI  PFTESTCD  PFTEST  PFSPCIES  PFSTRAIN  …  PFGENLOC  PFORRES  PFORREF 
1  P7081  PF  P7081-06345  2  ABC-004  PROTEIN  NS5B  AA  Amino Acid  HCV  1a  …  71  Ser  Ile 
2  P7081  PF  P7081-06345  1  ABC-004  PROTEIN  NS5B  NUC  Nucleotide  HCV  1a  …  213  -  A 
3  P7081  PF  P7081-06345  1  ABC-009  GENE  CYP3A5  AA  Amino Acid      …  152  Gly  Trp 
4  P7081  PF  P7081-06345  2  ABC-009  GENE  CYP3A5  NUC  Nucleotide      …  454  -  T 
 
Row  PFSTRESC  PFREFSEQ  PFREFSEQ  PFRCVNM  PFRESCAT  PFNAM  PFMETHOD  PFRUNID  PFBLFL  VISITNUM  PFDTC 
1 (cont)  NP_001234:p.Ile71Serfs  NP_001234  rs1110222  dbSNP  Frame Shift  Acme Genetics  Massively Parallel Sequencing  D391395-001  Y  1  2014-04-01 
2 (cont)  NM_005678:c.213delA  NM_005678  rs1110222  dbSNP  Deletion  Acme Genetics  Massively Parallel Sequencing  D391395-001  Y  1  2014-04-01 
3 (cont)  NC_000097.3:p.Trp152Glyfs  NP_000097.3  rs5030655  dbSNP  Frame Shift  Acme Genetics  Massively Parallel Sequencing  D391395-005  Y  1  2014-04-01 
4 (cont)  NM_000106.5:c.454delT  NM_000106.5  rs5030655  dbSNP  Deletion  Acme Genetics  Massively Parallel Sequencing  D391395-005  Y  1  2014-04-01 
 
Example 4 
This example shows nucleotide reads for two subjects using Wave Sequencing. While HGVS recommends that all variations for an individual be given in a 
single line, the PF domain holds one record per result. Therefore, the results in PFSTRESC, though in HGVS nomenclature, are recorded independent of each 
other, as if each variation were the only variation observed. When no difference from the reference sequence has been found in the exon specified by 
PFGENSRI, NVP (for “no variant present”) is used in the PFORRES variable; HGVS represents this with an equals sign (=).  
 
Rows 1-7:  Show the variations found in first subject’s TP53 gene. Note that there are two records for exon 4 because two variations were found.  
Row 8:  Shows the variation found in exon 2 in the first subject’s KRAS gene.  
Rows 8-14:  Show the variations found in the second subject’s TP53 gene. Note that no variations were found in exon 5 (row 10).  
Row 15:  Shows that no variations were found in exon 2 of the second subject’s KRAS gene. 
 
Row  STUDYID  DOMAIN  USUBJID  PFSEQ  PFREFID  PFTESTCD  PFTEST  PFGENTYP  PFGENRI  PFGENSRI  PFCAT  PFGENLOC 
1  ABCC  PF  ABCC-XY1  1  AA481093-21-XXX1  NUC  NUCLEOTIDE  GENE  TP53  EXON 4  GENETIC VARIATION  215 
2  ABCC  PF  ABCC-XY1  2  AA481093-21-XXX1  NUC  NUCLEOTIDE  GENE  TP53  EXON 4  GENETIC VARIATION  155_156 
3  ABCC  PF  ABCC-XY1  3  AA481093-21-XXX1  NUC  NUCLEOTIDE  GENE  TP53  EXON 5  GENETIC VARIATION  469 
4  ABCC  PF  ABCC-XY1  4  AA481093-21-XXX1  NUC  NUCLEOTIDE  GENE  TP53  EXON 6  GENETIC VARIATION  639 
5  ABCC  PF  ABCC-XY1  5  AA481093-21-XXX1  NUC  NUCLEOTIDE  GENE  TP53  EXON 7  GENETIC VARIATION  700_702 
6  ABCC  PF  ABCC-XY1  6  AA481093-21-XXX1  NUC  NUCLEOTIDE  GENE  TP53  EXON 8  GENETIC VARIATION  673-1 
7  ABCC  PF  ABCC-XY1  7  AA481093-21-XXX1  NUC  NUCLEOTIDE  GENE  TP53  EXON 9  GENETIC VARIATION  993+12 
8  ABCC  PF  ABCC-XY1  8  AA481093-21-XXX1  NUC  NUCLEOTIDE  GENE  KRAS  EXON 2  GENETIC VARIATION  34 
9  ABCC  PF  ABCC-XY2  1  AA811854-21-XXX2  NUC  NUCLEOTIDE  GENE  TP53  EXON 4  GENETIC VARIATION  188_194 
10  ABCC  PF  ABCC-XY2  2  AA811854-21-XXX2  NUC  NUCLEOTIDE  GENE  TP53  EXON 5  GENETIC VARIATION   
11  ABCC  PF  ABCC-XY2  3  AA811854-21-XXX2  NUC  NUCLEOTIDE  GENE  TP53  EXON 6  GENETIC VARIATION  639 
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Row  STUDYID  DOMAIN  USUBJID  PFSEQ  PFREFID  PFTESTCD  PFTEST  PFGENTYP  PFGENRI  PFGENSRI  PFCAT  PFGENLOC 
12  ABCC  PF  ABCC-XY2  4  AA811854-21-XXX2  NUC  NUCLEOTIDE  GENE  TP53  EXON 7  GENETIC VARIATION  743 
13  ABCC  PF  ABCC-XY2  5  AA811854-21-XXX2  NUC  NUCLEOTIDE  GENE  TP53  EXON 8  GENETIC VARIATION  873 
14  ABCC  PF  ABCC-XY2  6  AA811854-21-XXX2  NUC  NUCLEOTIDE  GENE  TP53  EXON 9  GENETIC VARIATION  926 
15  ABCC  PF  ABCC-XY2  7  AA811854-21-XXX2  NUC  NUCLEOTIDE  GENE  KRAS  EXON 2  GENETIC VARIATION   
 
Row  PFORRES  PFSTRESC  PFORREF  PFREFSEQ  PFRESCV  PFRCVNM  PFNAM  PFSPEC  PFMETHOD  VISITNUM  VISIT  PFDTC 
1 (cont)  G  NM_000546.5:c.215C>G  C  NM_000546.5  rs1042522  dbSNP  Vendor A  DNA  WAVE-Sequencing  -1  Pre-Treatment  2012-04-01 
2 (cont)  -  NM_000546.5:c.155_156del  AA  NM_000546.5      Vendor A  DNA  WAVE-Sequencing  -1  Pre-Treatment  2012-04-01 
3 (cont)  T  NM_000546.5:c.469G>T  G  NM_000546.5      Vendor A  DNA  WAVE-Sequencing  -1  Pre-Treatment  2012-04-01 
4 (cont)  G  NM_000546.5:c.639A>G  A  NM_000546.5  rs1800572  dbSNP  Vendor A  DNA  WAVE-Sequencing  -1  Pre-Treatment  2012-04-01 
5 (cont)  -  NM_000546.5:c.700_702del  TAC  NM_000546.5      Vendor A  DNA  WAVE-Sequencing  -1  Pre-Treatment  2012-04-01 
6 (cont)  C  NM_000546.5:c.673-1G>C  G  NM_000546.5      Vendor A  DNA  WAVE-Sequencing  -1  Pre-Treatment  2012-04-01 
7 (cont)  C  NM_000546.5:c.993+12T>C  T  NM_000546.5  rs1800899  dbSNP  Vendor A  DNA  WAVE-Sequencing  -1  Pre-Treatment  2012-04-01 
8 (cont)  T  NM_033360.2 :c.34G>T  G  NM_033360.2      Vendor A  DNA  WAVE-Sequencing  -1  Pre-Treatment  2012-04-01 
9 (cont)  -  NM_000546.5:c.188_194del  CTCCCAG  NM_000546.5      Vendor A  DNA  WAVE-Sequencing  -1  Pre-Treatment  2012-04-01 
10 (cont)  NVP  NM_000546.5:c.=    NM_000546.5      Vendor A  DNA  WAVE-Sequencing  -1  Pre-Treatment  2012-04-01 
11 (cont)  G  NM_000546.5:c.639A>G  A  NM_000546.5  rs1800372  dbSNP  Vendor A  DNA  WAVE-Sequencing  -1  Pre-Treatment  2012-04-01 
12 (cont)  A  NM_000546.5:c.743G>A  G  NM_000546.5  rs11540652  dbSNP  Vendor A  DNA  WAVE-Sequencing  -1  Pre-Treatment  2012-04-01 
13 (cont)  -  NM_000546.5:c.873delG  G  NM_000546.5      Vendor A  DNA  WAVE-Sequencing  -1  Pre-Treatment  2012-04-01 
14 (cont)  -  NM_000546.5:c.926delC  C  NM_000546.5      Vendor A  DNA  WAVE-Sequencing  -1  Pre-Treatment  2012-04-01 
15 (cont)  NVP  NM_033360.2 :c.=    NM_033360.2      Vendor A  DNA  WAVE-Sequencing  -1  Pre-Treatment  2012-04-01 
 
Example 5 
A polymerase chain reaction (PCR) is a common method for amplifying DNA. Quantitative PCR and DNA microarray are modern methodologies for studying 
gene expression. The amount of expressed gene in a cell can be measured by the number of copies of mRNA transcript of that gene present in a sample. In 
mRNA-based PCR, the RNA sample is first reverse-transcribed to cDNA. Then the cDNA is quantified via conventional PCR in a thermal cycler. This method is 
referred to as qRT-PCR (quantitative reverse-transcriptase polymerase chain reaction). The rate of generation of the amplified product is measured at each PCR 
cycle and the number of cycles required to reach a defined signal threshold is referred to as cycle time (Ct). The data generated can be analyzed by computer 
software to calculate relative gene expression (mRNA copy number) in several samples which is actually the measurement of the quantity of cDNA produced by 
the reverse-transcriptase step of the assay.  
 
Rows 1, 7:  Report on the copy number. 
Rows 4-6, 10-12:  Show the raw Ct values. 
Rows 3, 9:  Show the mean Ct value.  
 
Row  STUDYID  DOMAIN  USUBJID  PFSEQ  PFREFID  PFTESTCD  PFTEST  REPNUM  PFGENTYP  PFGENRI  PFGENSRI  PFCAT 
1  AAA  PF  AAA-XXX1  1  L1046058-3-S0072248  COPYNUM  Copy Number    GENE  MYC  EXON Boundary 2-3  GENE EXPRESSION 
4  AAA  PF  AAA-XXX1  4  L1046058-3-S0072248  RAWCT  Raw Ct Value  1  GENE  MYC  EXON Boundary 2-3  GENE EXPRESSION 
5  AAA  PF  AAA-XXX1  5  L1046058-3-S0072248  RAWCT  Raw Ct Value  2  GENE  MYC  EXON Boundary 2-3  GENE EXPRESSION 
6  AAA  PF  AAA-XXX1  6  L1046058-3-S0072248  RAWCT  Raw Ct Value  3  GENE  MYC  EXON Boundary 2-3  GENE EXPRESSION 
3  AAA  PF  AAA-XXX1  3  L1046058-3-S0072248  MEANCT  Mean Ct Value    GENE  MYC  EXON Boundary 2-3  GENE EXPRESSION 
7  AAA  PF  AAA-XXX1  7  L1046058-3-S0072248  COPYNUM  Copy Number    GENE  MFNG  EXON Boundary 4-5  GENE EXPRESSION 
10  AAA  PF  AAA-XXX1  10  L1046058-3-S0072248  RAWCT  Raw Ct Value  1  GENE  MFNG  EXON Boundary 4-5  GENE EXPRESSION 
11  AAA  PF  AAA-XXX1  11  L1046058-3-S0072248  RAWCT  Raw Ct Value  2  GENE  MFNG  EXON Boundary 4-5  GENE EXPRESSION 
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Row  STUDYID  DOMAIN  USUBJID  PFSEQ  PFREFID  PFTESTCD  PFTEST  REPNUM  PFGENTYP  PFGENRI  PFGENSRI  PFCAT 
12  AAA  PF  AAA-XXX1  12  L1046058-3-S0072248  RAWCT  Raw Ct Value  3  GENE  MFNG  EXON Boundary 4-5  GENE EXPRESSION 
9  AAA  PF  AAA-XXX1  9  L1046058-3-S0072248  MEANCT  Mean Ct Value    GENE  MFNG  EXON Boundary 4-5  GENE EXPRESSION 
 
Row  PFORRES  PFORRESU  PFSTRESC  PFSTRESN  PFSTRESU  PFNAM  PFSPEC  PFMETHOD  PFRUNID  VISIT  VISITNUM  PFDTC 
1  34.07  Copies/ng  34.07  34.07  Copies/ng  Vendor B  RNA  qRT-PCR  Hs00153408_m1  Pre-Treatment  -1  2013:01:30:19:56:00 
4  26.595144  Cycles  26.595144  26.595144  Cycles  Vendor B  RNA  qRT-PCR  Hs00153408_m1  Pre-Treatment  -1  2013:01:30:19:56:00 
5  26.098644  Cycles  26.098644  26.098644  Cycles  Vendor B  RNA  qRT-PCR  Hs00153408_m1  Pre-Treatment  -1  2013:01:30:19:56:00 
6  26.399672  Cycles  26.399672  26.399672  Cycles  Vendor B  RNA  qRT-PCR  Hs00153408_m1  Pre-Treatment  -1  2013:01:30:19:56:00 
3  26.364487  Cycles  26.364487  26.364487  Cycles  Vendor B  RNA  qRT-PCR  Hs00153408_m1  Pre-Treatment  -1  2013:01:30:19:56:00 
7  0.67  Copies/ng  0.67  0.67  Copies/ng  Vendor B  RNA  qRT-PCR  Hs00159117_m1  Pre-Treatment  -1  2013:02:30:19:56:00 
10  32.979595  Cycles  32.979595  32.979595  Cycles  Vendor B  RNA  qRT-PCR  Hs00159117_m1  Pre-Treatment  -1  2013:02:30:19:56:00 
11  33.54182  Cycles  33.54182  33.54182  Cycles  Vendor B  RNA  qRT-PCR  Hs00159117_m1  Pre-Treatment  -1  2013:02:30:19:56:00 
12  33.4799  Cycles  33.4799  33.4799  Cycles  Vendor B  RNA  qRT-PCR   Hs00159117_m1  Pre-Treatment  -1  2013:02:30:19:56:00 
9  33.33377  Cycles  33.33377  33.33377  Cycles  Vendor B  RNA  qRT-PCR  Hs00159117_m1  Pre-Treatment  -1  2013:02:30:19:56:00 
 
Example 6 
This example contains gene expression data obtained using a two-color (two-channel) microarray. A microarray is a type of lab-on-a-chip, in which the results 
initially appear as a field of dots of varying intensity and hue, as in the figure below. Single-color (single-channel) microarrays are also available; the results they 
produce are similar, but vary only in intensity.  
 
 
Figure 2: Sample Two-Color Microarray‡ 
Interpretation of the microarray requires a specialized scanner which converts the color and brightness of each dot into numeric intensity values. Some scanners 
normalize the values as part of the process. Because a single microarray can hold thousands of results, a vendor may choose to report only the “interesting” 
results (e.g. wells that showed over-expression), which can be determined with specialized analytic software, often sold by the same company that produced the 
microarray chip and/or the scanner. In this example, AGM-G4851B is the SPDEVID of the microarray kit, AGS- G4900DA is the SPDEVID of the scanner, and 
‡ Public domain. Originally released by the National Cancer Institute. 
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MANAN03 is the SPDEVID of the workstation to which the scanner is connected, and on which the vendor’s analytic software is installed. Because the analysis 
was performed by the vendor and not by the sponsor, there is no derived value flag.  
 
Row 1:  Shows the target sequence being tested. Because the sequence is 60 characters long, for the purposes of this example it has been omitted from 
PFSTRESC.  
Rows 2-3:   Show the intensity values for each channel, or color.  
Row 4:   Shows the p-value.  
Row 5:  Shows the fold change. 
 
Row  STUDYID  DOMAIN  USUBJID  SPDEVID  PFSEQ  PFGRPID  PFREFID  PFTESTCD  PFTEST  PFCAT  PFORRES 
1  A12345  PF  43871  AGM-G4851B  1  1  2287.09443  ACTSEQ  Active Sequence  Pre-Analytic 
GGGAGAGAAGAGACCTGCCA 
GATTATCAGACCTCTTCATG 
TTAAAAGACCATCTCCTGTA 
2  A12345  PF  43871  AGS- G4900DA  2  1  2287.09443  NINT1VAL  Normalized Intensity 1 Value  Pre-Analytic  1.16279 
3  A12345  PF  43871  AGS- G4900DA  3  1  2287.09443  NINT2VAL  Normalized Intensity 2 Value  Pre-Analytic  0.96469 
4  A12345  PF  43871  MANAN03  4  1  2287.09443  PVAL  P Value  Analytic  0.05391 
5  A12345  PF  43871  MANAN03  5  1  2287.09443  FOLDCHG  Fold Change  Analytic  1.8 
 
Row  PFSTRESC  PFSTRESN  PFXFN  PFNAM  PFSPEC  PFMETHOD  PFRUNID  PFANMETH  PFBLFL  VISITNUM  PFDTC 
1 (cont)  …    2.16.090.1.135764.3.4:7280912  Deluxe Central Labs  RNA  Microarray  1000450001      2  2005-03-21T11:28:17 
2 (cont)  1.16279  1.16279  2.16.090.1.135764.3.4:7280912  Deluxe Central Labs  RNA  Microarray  1000450001  LOWESS    2  2005-03-21T11:28:17 
3 (cont)  0.96469  0.96469  2.16.090.1.135764.3.4:7280912  Deluxe Central Labs  RNA  Microarray  1000450001  LOWESS    2  2005-03-21T11:28:17 
4 (cont)  0.05391  0.05391  2.16.090.1.135764.3.4:7280912  Deluxe Central Labs  RNA  Microarray  1000450001      2  2005-03-21T11:28:17 
5 (cont)  1.8  1.8  2.16.090.1.135764.3.4:7280912  Deluxe Central Labs  RNA  Microarray  1000450001      2  2005-03-21T11:28:17 
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